Below is a sample of the emails you can expect to receive when signed up to Danaher.
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Jul 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=qvjB8RDrxpmjIjYtbWf0K9z61-TpdBQ_
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Jul 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=pVTJbpgsd5nfIj0LSywGZvfdvLbPgT8v
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jul 29, 2019 (4:01pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Jul 29, 2019, at $142.68
Monday Jul 29, 2019 |
$142.68 Close Price |
$0.40 (0.28%) Change |
$141.64 - $143.19 Day's Range |
1.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=sZJ7VgPv75lXIhV8Fuz1Qsn7H98RPn1X
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Jul 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=3UJMdzRyM5kUIn8RsqOOVyq3CN10AUfG
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Jul 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ANgAKjRvRpnoIibAOjE3xy28iLCMpU_-
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Jul 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=jcFaXVd2fJnjIoPG9o531cSKgdKyAmEv
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Jul 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=GsxgzRyTZZnvIpoZMmNVz1ccjb6PdZdh
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Jul 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=BKvxueH2wJn5IjqpjtZ0xp1otRFGZWD2
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 9, 2019 (4:04pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 9, 2019, at $140.31
Friday Aug 9, 2019 |
$140.31 Close Price |
($0.58) (-0.41%) Change |
$139.19 - $141.51 Day's Range |
1.3M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Fvqv36vFR5llIi9PiJCyQ25kpRRuhRhB
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 5, 2019 (4:03pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 5, 2019, at $135.70
Monday Aug 5, 2019 |
$135.70 Close Price |
($3.49) (-2.51%) Change |
$134.11 - $137.96 Day's Range |
2.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=q62YDuJpwZnKIiKndm146ppWkPiXIZDy
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 8, 2019 (4:03pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 8, 2019, at $140.89
Thursday Aug 8, 2019 |
$140.89 Close Price |
$2.69 (1.95%) Change |
$138.61 - $141.07 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=G4jANqFR-JlsIh9-2-OaAyQe-qLbw0p3
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 7, 2019 (4:02pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 7, 2019, at $138.20
Wednesday Aug 7, 2019 |
$138.20 Close Price |
($0.03) (-0.02%) Change |
$134.50 - $138.68 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=bWZhdvXr-JmrIo-023HTP9I8HK0xI4Cq
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 6, 2019 (4:02pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 6, 2019, at $138.23
Tuesday Aug 6, 2019 |
$138.23 Close Price |
$2.53 (1.86%) Change |
$135.79 - $138.25 Day's Range |
3.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=7nWv7KTPp5n2Iv3okRW03uleCba0mGdT
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jul 31, 2019 (4:04pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Jul 31, 2019, at $140.50
Wednesday Jul 31, 2019 |
$140.50 Close Price |
($2.20) (-1.54%) Change |
$139.27 - $142.78 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=DqHVeZBz05njIgLiwtzjVuKDG7KpSUXs
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 1, 2019 (4:01pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 1, 2019, at $140.22
Thursday Aug 1, 2019 |
$140.22 Close Price |
($0.28) (-0.20%) Change |
$139.14 - $142.36 Day's Range |
2.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=pTnBusnjJZm3InDIpdlKXiNLhmKzxTTG
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 2, 2019 (4:04pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 2, 2019, at $139.19
Friday Aug 2, 2019 |
$139.19 Close Price |
($1.03) (-0.73%) Change |
$138.63 - $140.43 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=mErVFVPnZJkSIjX8NtdYwLrDOD569byS
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jul 30, 2019 (4:01pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Jul 30, 2019, at $142.70
Tuesday Jul 30, 2019 |
$142.70 Close Price |
$0.02 (0.01%) Change |
$141.46 - $143.08 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=2dBmnKwET5myIsTFWpGrMKAJrdWmomwE
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 12, 2019 (3:59pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 12, 2019, at $138.44
Monday Aug 12, 2019 |
$138.44 Close Price |
($1.87) (-1.33%) Change |
$138.03 - $140.72 Day's Range |
1.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=YCuWrtXYzpnzIi0O1Z24dCBloK7mOHbz
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 13, 2019 (4:02pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 13, 2019, at $140.54
Tuesday Aug 13, 2019 |
$140.54 Close Price |
$2.13 (1.54%) Change |
$137.72 - $141.44 Day's Range |
1.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=bVw2aVd3KpkUIpUMtGAbId2jfydilbsh
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 14, 2019 (4:02pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 14, 2019, at $136.36
Wednesday Aug 14, 2019 |
$136.36 Close Price |
($4.18) (-2.97%) Change |
$136.29 - $140.24 Day's Range |
2.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=rG3H6qtJN5nrInFAvTgNV7dWt0j_XxSa
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 15, 2019 (4:01pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 15, 2019, at $137.19
Thursday Aug 15, 2019 |
$137.19 Close Price |
$0.83 (0.61%) Change |
$136.48 - $139.40 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=WG3kxcEkSJnTIrNe4RcdjXW3SVwD418H
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 16, 2019 (4:03pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 16, 2019, at $140.35
Friday Aug 16, 2019 |
$140.35 Close Price |
$3.16 (2.30%) Change |
$137.88 - $140.55 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=uAbxBaty6JkcIp27xAE6LRjBD_1Kb4dA
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 20, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 20, 2019, at $140.07
Tuesday Aug 20, 2019 |
$140.07 Close Price |
($1.64) (-1.16%) Change |
$140.00 - $142.50 Day's Range |
1.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=k4ja9jWvgpn2Ipl-QEyr9m7li0euOtf1
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 19, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 19, 2019, at $141.71
Monday Aug 19, 2019 |
$141.71 Close Price |
$1.36 (0.97%) Change |
$140.23 - $142.14 Day's Range |
1.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=HEHM6ewKE5nqIufx6_ORg29qnXSvHKV9
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 21, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 21, 2019, at $140.32
Wednesday Aug 21, 2019 |
$140.32 Close Price |
$0.25 (0.18%) Change |
$139.20 - $141.58 Day's Range |
1.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Km8ZAHBbq5knIgPBWXElV8-R0PZ2gIP-
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Aug 21, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=buuwM3Nm8JklIjtZR8j4Fs9qD8jWSAJl
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 22, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 22, 2019, at $139.56
Thursday Aug 22, 2019 |
$139.56 Close Price |
($0.76) (-0.54%) Change |
$138.77 - $141.55 Day's Range |
1.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=MCUNssyadJkZIuHrGITgSSkz71BjM7Qc
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 424B5 filed on Aug 23, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=n8Gub4Ng4pmDItT9_zaycEdFog2gbxOy
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 23, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 23, 2019, at $135.40
Friday Aug 23, 2019 |
$135.40 Close Price |
($4.16) (-2.98%) Change |
$134.54 - $140.20 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=zazny3esipklIgcoaO42cjsOWlScDnOR
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Aug 26, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=29z4x4RE7JksIsD9rf7ylWAGqop3Bby_
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 26, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 26, 2019, at $136.40
Monday Aug 26, 2019 |
$136.40 Close Price |
$1.00 (0.74%) Change |
$134.97 - $136.95 Day's Range |
1.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=f9dt4duR95kNIlUfp4m9oA76GIjsBR0S
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 27, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 27, 2019, at $138.25
Tuesday Aug 27, 2019 |
$138.25 Close Price |
$1.85 (1.36%) Change |
$137.01 - $138.80 Day's Range |
3.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=GfYMaeYAepnVImAKvmqsoRGmUttmcfAU
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 28, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 28, 2019, at $139.49
Wednesday Aug 28, 2019 |
$139.49 Close Price |
$1.24 (0.90%) Change |
$137.25 - $139.79 Day's Range |
1.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=pr8ncTVueplQIrBfjWsro_L2_R25QTTs
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Aug 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=rqR83TpGUpkuImitJXzRCfZ3yz_VdnNa
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 29, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 29, 2019, at $141.68
Thursday Aug 29, 2019 |
$141.68 Close Price |
$2.19 (1.57%) Change |
$140.05 - $142.28 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=CaCWvr3MVZmMIubwxu8wjjP8yPBAjzBq
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Aug 30, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Aug 30, 2019, at $142.09
Friday Aug 30, 2019 |
$142.09 Close Price |
$0.41 (0.29%) Change |
$141.22 - $143.38 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=fCMdUh4PuZkUIleUYTDP73Qrv2OaDTGP
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form FWP filed on Sep 3, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=eJa9d6GB4ZkUIuQ7NuT3NgXthHrOZUh_
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 3, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 3, 2019, at $139.87
Tuesday Sep 3, 2019 |
$139.87 Close Price |
($2.22) (-1.56%) Change |
$138.97 - $141.00 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=YJZFKgGzqZkJIuuHQi3CshtLXWcs-jo2
News Release Issued: Sep 3, 2019 (9:10pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-09-03-Danaher-Announces-Pricing-Of-Euro-Denominated-Senior-Notes-Offering
WASHINGTON, Sept. 3, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that its wholly-owned subsidiary, DH Europe Finance II S.à r.l. ("Danaher International II"), has priced an offering of:
Danaher estimates that the net proceeds from the sale of the senior notes in this offering will be approximately €6.197 billion, after deducting the underwriting discounts and estimated offering expenses payable by Danaher. Danaher anticipates using the net proceeds to fund a portion of the cash consideration payable for, and certain costs associated with, its acquisition of the Biopharma Business of GE Life Sciences (the "GE Biopharma Acquisition"). Pending completion of the GE Biopharma Acquisition, Danaher may invest the net proceeds of the offering in short-term bank deposits or invest them in interest-bearing, investment-grade securities. The senior notes will be fully and unconditionally guaranteed on a senior unsecured basis by Danaher. The offering is expected to close on September 18, 2019, subject to customary closing conditions.
The offering is being made pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission.
The offering of senior notes may be made only by means of a prospectus and prospectus supplement. A copy of the prospectus and prospectus supplement relating to the securities can be obtained from Barclays Bank PLC at Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: 1-888-603-5847; BNP Paribas at 10 Harewood Avenue, London NW1 6AA, United Kingdom, Attention: Fixed Income Syndicate, Phone: 1-800-854-5674; Citigroup Global Markets Limited c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by calling 1 (800) 831-9146 or by email at prospectus@citi.com; Deutsche Bank AG, London Branch at Winchester House, 1 Great Winchester Street, London EC2N 2DB, Attention: Syndicate Desk, Phone: +44-20-7545-4361, Fax: +44-20-7545-4455; or Banco Santander, S.A., Ciudad Grupo Santander, Avenida de Cantabria s/n, Boadilla del Monte, Madrid, Spain, Attention: Syndicate Desk, Phone: +34-91-257-2029 or +44-20-7756-6802.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, the senior notes or any other securities, nor shall there be any offer, solicitation or sale of any security mentioned in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the offering of the senior notes, the anticipated use of proceeds and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking statements" within the meaning of the federal securities laws. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher's SEC filings, including Danaher's 2018 Annual Report on Form 10-K and Danaher's Quarterly Reports on Form 10-Q for the first and second quarters of 2019. These forward-looking statements speak only as of the date of this release and Danaher and Danaher International II do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=VE7CMBtTA5nxIu0fCeLjSbgkGECG-uNf
News Release Issued: Sep 4, 2019 (7:14am EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-09-04-Envista-Announces-Launch-of-IPO-Roadshow
BREA, Calif., Sept. 4, 2019 /PRNewswire/ -- Envista Holdings Corporation, a subsidiary of Danaher Corporation (NYSE: DHR), today announced it has launched a roadshow for the initial public offering (IPO) of its common stock.
Envista is offering 26,768,000 shares of its common stock in the IPO. The underwriters will also have a 30-day option to purchase up to 4,015,200 additional shares of common stock at the IPO price, less underwriting discounts and commissions. The IPO price is currently expected to be between $21.00 and $24.00 per share. Envista expects to list its common stock on the New York Stock Exchange under the ticker symbol "NVST."
Following the IPO, Danaher is expected to hold approximately 82.7% of Envista (80.6% if the underwriters' overallotment option is exercised in full). The net proceeds from the IPO are expected to be paid to Danaher as partial consideration for the dental businesses that Danaher is transferring to Envista in connection with the IPO.
J.P. Morgan, Goldman Sachs & Co. LLC and Morgan Stanley are joint lead book-running managers for the offering. Baird, Evercore ISI and Jefferies are book-running managers for the offering. BofA Merrill Lynch, Credit Suisse, Stifel and William Blair are co-managers for the offering.
The offering will be made only by means of a prospectus. Copies of the preliminary prospectus related to the offering may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com;
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, email: prospectus-ny@ny.email.gs.com, telephone: 1-866-471-2526, fax: 1-212-902-9316; or
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014.
A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission (SEC) but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT ENVISTA
Envista is a global dental products company that develops and provides a comprehensive portfolio of dental consumables, equipment and services to dental professionals covering an estimated 90% of dentists' clinical needs for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. Envista's operating companies, Nobel Biocare Systems, Ormco and KaVo Kerr, serve more than one million dentists in over 150 countries.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. These statements relate to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the offering. There can be no guarantees that the IPO will be consummated on the timeline anticipated or at all or that Danaher will achieve the anticipated benefits of the IPO. Danaher's ability to consummate and achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operation or financial condition of Envista or Danaher, changes in the dental products industry, adverse market or macroeconomic conditions and other factors outside Danaher's control that could affect the advisability, pricing and timing of the potential IPO. Each of Danaher and Envista undertakes no duty to update forward-looking statements, except as may be required by law.
SOURCE Danaher Corporation; Envista Holdings Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=dKTkcATqH5nBIhjqnA4_p2JOHv1wVuHd
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 4, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 4, 2019, at $140.26
Wednesday Sep 4, 2019 |
$140.26 Close Price |
$0.39 (0.28%) Change |
$139.44 - $142.00 Day's Range |
1.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=AKruDNwpSpkUIoKt7oyo3Nm6eX5yeC4-
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Sep 5, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=XwDtWwGRwZnpIv1OXl367AvUYsQT2Z3C
Hi ,
Do you handle email list purchase/data append projects at your company?
Target Industry: _____________
Target Geography: ______________
Target Job Title: ________________
I'll arrange for a few samples, counts and pricing
Waiting to hear from you.
Regards,
Janet
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 424B5 filed on Sep 5, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=zmRMtXkTGJmQIshdgMmXiiS_0zPFtnVY
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 6, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 6, 2019, at $144.33
Friday Sep 6, 2019 |
$144.33 Close Price |
$1.38 (0.97%) Change |
$143.12 - $144.93 Day's Range |
1.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=huX23GUGG5lWIqsjKg5p_I0zGM7TawKr
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 10, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 10, 2019, at $136.59
Tuesday Sep 10, 2019 |
$136.59 Close Price |
($2.77) (-1.99%) Change |
$133.84 - $138.36 Day's Range |
3.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=vc7pDEyq0ZmIIg0ZXPRErteTD4CpTJqz
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form CERT filed on Sep 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=u3cnHhevfJn-In2rCRDMU-AzbQfj5Li6
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 3 filed on Sep 17, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=TbErnzE8YplvIsGlkeC4zFR2Pqt50z_H
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Sep 10, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ZX3FwTnEIpndIiENAJaY1wsEyVTonJQN
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 13, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 13, 2019, at $141.02
Friday Sep 13, 2019 |
$141.02 Close Price |
($0.72) (-0.51%) Change |
$140.02 - $142.75 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=yVNERk23yZmGIthAkuwbw_1eDYi0J01e
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 12, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 12, 2019, at $141.74
Thursday Sep 12, 2019 |
$141.74 Close Price |
$2.24 (1.61%) Change |
$140.11 - $142.15 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=B9FBqC4usJkeInInjCUIIpjH8t_dOLA-
Hi ,
Any interest on my previous? Please advise
Regards,
Janet
From: Janet Chua [mailto:janet.chua@internationalb2bprospects.com]
Sent: Thursday, September 5, 2019 6:35 AM
To: '@'
Subject: Campaign for Q3
Hi ,
Do you handle email list purchase/data append projects at your company?
Target Industry: _____________
Target Geography: ______________
Target Job Title: ________________
I'll arrange for a few samples, counts and pricing
Waiting to hear from you.
Regards,
Janet
News Release Issued: Sep 9, 2019 (4:35pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-09-09-Danaher-To-Webcast-Water-Quality-Platform-Investor-And-Analyst-Meeting-At-Hach
WASHINGTON, Sept. 9, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) will host a live video webcast of its Water Quality Platform Investor and Analyst Meeting at Hach on September 17, 2019 beginning at 8:00 a.m. MT. The event will be held at Danaher's Hach facility in Loveland, Colorado and hosted by Joakim Weidemanis, Executive Vice President of the Water Quality and Product Identification platforms, and Matt McGrew, Executive Vice President and Chief Financial Officer. A link to the webcast and accompanying slide presentation will be available on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the video webcast will be available following the presentation.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and our Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=TJKh6zMx8Jl6ImUoawhfaEEuKQkzmv9m
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 17, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 17, 2019, at $142.33
Tuesday Sep 17, 2019 |
$142.33 Close Price |
$1.68 (1.19%) Change |
$140.52 - $142.71 Day's Range |
1.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=g3BKhYvHKJl2IoA9Q7NG0NuuQQhgjMhs
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 5, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 5, 2019, at $142.95
Thursday Sep 5, 2019 |
$142.95 Close Price |
$2.69 (1.92%) Change |
$140.99 - $143.45 Day's Range |
1.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Ad72WjsTEJnaIm4p8QRoObQ2j-kLQlqA
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-A12B filed on Sep 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=bH4VtGGHPJl6IqkmHtJyHWzDnbQM8JWZ
Hi ,
Any interest on my previous? Please advise
Regards,
Janet
From: Janet Chua [mailto:janet.chua@internationalb2bprospects.com]
Sent: Thursday, September 5, 2019 6:35 AM
To: '@'
Subject: Campaign for Q3
Hi ,
Do you handle email list purchase/data append projects at your company?
Target Industry: _____________
Target Geography: ______________
Target Job Title: ________________
I'll arrange for a few samples, counts and pricing
Waiting to hear from you.
Regards,
Janet
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 18, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 18, 2019, at $143.95
Wednesday Sep 18, 2019 |
$143.95 Close Price |
$1.62 (1.14%) Change |
$141.83 - $144.76 Day's Range |
2.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=xqkV36G9W5neIpxu063KSyCl6bM1MH6E
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 11, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 11, 2019, at $139.50
Wednesday Sep 11, 2019 |
$139.50 Close Price |
$2.91 (2.13%) Change |
$135.48 - $139.76 Day's Range |
2.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=yzDvB8zwmZnRIk_0MRml3qgkhq0P3pmd
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 9, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 9, 2019, at $139.36
Monday Sep 9, 2019 |
$139.36 Close Price |
($4.97) (-3.44%) Change |
$139.08 - $144.27 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=G838qYuaIJmiIifBxSFkdNJjzN5eJ2tS
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Sep 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=vaJJtfK2IJkhIvRjpHGwLpgobGh77BNo
News Release Issued: Sep 10, 2019 (4:15pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-09-10-Danaher-Announces-Quarterly-Dividend
WASHINGTON, Sept. 10, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.17 per share of its common stock, payable on October 25, 2019 to holders of record on September 27, 2019. In addition, Danaher announced today that its Board of Directors has approved a quarterly cash dividend of $11.875 per share of its 4.75% Series A Mandatory Convertible Preferred Stock, payable on October 15, 2019 to holders of record on September 30, 2019.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=vZmvhZ4J-JkuIjnsSdeehC-d6Dx1nh_o
News Release Issued: Sep 17, 2019 (7:51pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-09-17-Envista-Announces-Pricing-of-Initial-Public-Offering
BREA, Calif., Sept. 17, 2019 /PRNewswire/ -- Envista Holdings Corporation, a subsidiary of Danaher Corporation (NYSE: DHR), announced today the pricing of its initial public offering (IPO) of 26,768,000 shares of its common stock at a price to the public of $22.00 per share. The shares are expected to begin trading on the New York Stock Exchange under the ticker symbol "NVST." The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $588,896,000, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on September 20, 2019, subject to customary closing conditions.
Envista has granted the underwriters a 30-day option to purchase up to 4,015,200 additional shares of common stock at the initial price to the public, less underwriting discounts and commissions.
Following the IPO, Danaher is expected to hold approximately 82.7% of Envista (80.6% if the underwriters' overallotment option is exercised in full). The net proceeds from the IPO are expected to be paid to Danaher as partial consideration for the dental businesses that Danaher is transferring to Envista in connection with the IPO.
J.P. Morgan, Goldman Sachs & Co. LLC and Morgan Stanley are joint lead book-running managers for the offering. Baird, Evercore ISI and Jefferies are book-running managers for the offering. BofA Merrill Lynch, Credit Suisse, Stifel and William Blair are co-managers for the offering.
The offering will be made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com;
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, email: prospectus-ny@ny.email.gs.com, telephone: 1-866-471-2526, fax: 1-212-902-9316; or
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014.
A registration statement relating to these securities was filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT ENVISTA
Envista is a global dental products company that develops and provides a comprehensive portfolio of dental consumables, equipment and services to dental professionals covering an estimated 90% of dentists' clinical needs for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. Envista's operating companies, Nobel Biocare Systems, Ormco and KaVo Kerr, serve more than one million dentists in over 150 countries.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. These statements relate to the offering and the use of proceeds therefrom. There are significant risks and uncertainties relating to the offering. There can be no guarantees that the IPO will be consummated on the timeline anticipated or at all or that Danaher will achieve the anticipated benefits of the IPO. Danaher's ability to consummate and achieve the anticipated benefits of the IPO may be materially affected by such factors as changes to the business, results of operation or financial condition of Envista or Danaher, changes in the dental products industry, adverse market or macroeconomic conditions and other factors outside Danaher's control. Each of Danaher and Envista undertakes no duty to update forward-looking statements, except as may be required by law.
SOURCE Danaher Corporation; Envista Holdings Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=B97pzCBn25n5Imou3ods4uZky8sCgA4E
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 16, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 16, 2019, at $140.65
Monday Sep 16, 2019 |
$140.65 Close Price |
($0.37) (-0.26%) Change |
$139.57 - $141.65 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=U8fjXwDc-pkdIq9C0OvQAn0rqhVmA911
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 19, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 19, 2019, at $145.75
Thursday Sep 19, 2019 |
$145.75 Close Price |
$1.80 (1.25%) Change |
$143.90 - $146.93 Day's Range |
2.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=BNwFUpRDSplhIphU6-7BNps4hgGceEeN
News Release Issued: Sep 20, 2019 (4:15pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-09-20-Envista-Announces-IPO-Closing
BREA, Calif., Sept. 20, 2019 /PRNewswire/ -- Envista Holdings Corporation, a subsidiary of Danaher Corporation (NYSE: DHR), today announced the closing of its previously announced initial public offering (IPO) of 26,768,000 shares of its common stock at a price to the public of $22.00 per share. In connection with the IPO, the underwriters exercised in full their option to purchase an additional 4,015,200 shares of common stock at the price to the public less underwriting discounts, bringing the total IPO size to 30,783,200 shares. The shares began trading on the New York Stock Exchange on September 18, 2019 under the ticker symbol "NVST."
As of the closing of the IPO, Danaher holds approximately 80.6% of Envista.
After deducting underwriting discounts and commissions payable by Envista, the net proceeds to Envista were approximately $643.4 million. The net proceeds from the IPO have been paid to Danaher as partial consideration for the dental businesses that Danaher transferred to Envista in connection with the IPO.
J.P. Morgan, Goldman Sachs & Co. LLC and Morgan Stanley acted as joint lead book-running managers for the offering. Baird, Evercore ISI and Jefferies acted as book-running managers for the offering. BofA Merrill Lynch, Credit Suisse, Stifel and William Blair acted as co-managers for the offering.
The offering was made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 866-803-9204 or by email at prospectus-eq_fi@jpmchase.com;
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, email: prospectus-ny@ny.email.gs.com, telephone: 1-866-471-2526, fax: 1-212-902-9316; or
Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, Second Floor, New York, New York 10014.
A registration statement relating to these securities was filed with, and declared effective by, the U.S. Securities and Exchange Commission (SEC). This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
ABOUT ENVISTA
Envista is a global dental products company that develops and provides a comprehensive portfolio of dental consumables, equipment and services to dental professionals covering an estimated 90% of dentists' clinical needs for diagnosing, treating and preventing dental conditions as well as improving the aesthetics of the human smile. Envista's operating companies, Nobel Biocare Systems, Ormco and KaVo Kerr, serve more than one million dentists in over 150 countries.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
SOURCE Danaher Corporation; Envista Holdings Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=e99fCtgUdJlSIvBilWTELuW2m5H9JsTD
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 20, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 20, 2019, at $146.47
Friday Sep 20, 2019 |
$146.47 Close Price |
$0.72 (0.49%) Change |
$145.83 - $147.33 Day's Range |
5.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=TXCn4PM8QZnaIngCg9AG-IW0o8G_7GyG
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Sep 20, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=VfTW49g68JmxIjDmh5lFGkbrEhqY3sEn
News Release Issued: Sep 23, 2019 (4:27pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-09-23-Danaher-Announces-Redemption-Of-Senior-Notes
WASHINGTON, Sept. 23, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that it will redeem all of its $500,000,000 aggregate principal amount of 2.400% Senior Notes due 2020 (the "Danaher 2020 Notes") and all of the $375,000,000 aggregate principal amount of 5.00% Senior Notes due 2020 originally issued by Pall Corporation and subsequently guaranteed by Danaher (the "Pall 2020 Notes" and together with the Danaher 2020 Notes, the "Notes"), in each case at a redemption price equal to the outstanding principal amount and a make-whole premium as specified in the applicable indenture, plus accrued and unpaid interest. The redemption date for the Notes will be October 24, 2019. Danaher intends to fund the redemption using a portion of the cash distribution it received in connection with the initial public offering of Envista Holdings Corporation, Danaher's Dental business.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ZKcyAXYnspm7Ii0w6xFYDhpATm30m_LT
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 23, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 23, 2019, at $144.60
Monday Sep 23, 2019 |
$144.60 Close Price |
($1.87) (-1.28%) Change |
$144.21 - $146.34 Day's Range |
1.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Zp3kkbygwZkrIvukibBubD3y5M4KmXjO
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 24, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 24, 2019, at $144.55
Tuesday Sep 24, 2019 |
$144.55 Close Price |
($0.05) (-0.03%) Change |
$143.07 - $146.19 Day's Range |
3.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=kRmeeJz4O5k8Io4Ykn7JZzw31QLeTI6f
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 25, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 25, 2019, at $143.95
Wednesday Sep 25, 2019 |
$143.95 Close Price |
($0.60) (-0.42%) Change |
$142.67 - $144.70 Day's Range |
2.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=KEag2mdsvJlsItX9MXR1w4xhHRg7gm9n
Hi,
Hope you are doing great.
Did you get a chance to review my previous email?
Please let me know your thoughts.
Thanks & Regards,
Alana Nelson.
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 27, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 27, 2019, at $141.56
Friday Sep 27, 2019 |
$141.56 Close Price |
($1.20) (-0.84%) Change |
$140.75 - $143.61 Day's Range |
1.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=q9w7ftBX5JkXIqzEA-lCD0OJHHcnN8n4
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 26, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 26, 2019, at $142.76
Thursday Sep 26, 2019 |
$142.76 Close Price |
($1.02) (-0.71%) Change |
$141.74 - $144.98 Day's Range |
1.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=pHpBRkTKqpl_IgiXgjoE0K3gYBEAcJdf
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 1, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 1, 2019, at $141.92
Tuesday Oct 1, 2019 |
$141.92 Close Price |
($2.51) (-1.74%) Change |
$141.76 - $145.36 Day's Range |
1.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=yNC9WwAsn5lUIghYcNxCwLgMfO5klxJG
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Sep 30, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Sep 30, 2019, at $144.43
Monday Sep 30, 2019 |
$144.43 Close Price |
$2.87 (2.03%) Change |
$141.83 - $145.15 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=GyRXNn3BM5m6IkIoH8NVCT8rkPykqBd3
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 4, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 4, 2019, at $141.65
Friday Oct 4, 2019 |
$141.65 Close Price |
$2.84 (2.05%) Change |
$139.21 - $141.73 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ygAKHhwT8pkjIjbt0HLeL53mEfo6NDRs
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 7, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 7, 2019, at $139.68
Monday Oct 7, 2019 |
$139.68 Close Price |
($1.97) (-1.39%) Change |
$139.65 - $141.13 Day's Range |
1.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=xxW3dAPv05mbIkkhTY91e_mzIB68ANeO
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 2, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 2, 2019, at $137.11
Wednesday Oct 2, 2019 |
$137.11 Close Price |
($4.81) (-3.39%) Change |
$136.47 - $141.08 Day's Range |
2.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=MaxJmqkVzpkIImSJcJ_fOsVBe4Z_V5rI
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 3, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 3, 2019, at $138.81
Thursday Oct 3, 2019 |
$138.81 Close Price |
$1.70 (1.24%) Change |
$135.33 - $138.84 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Eznvcy9avZlIIkUDrKAPg_5b2RlmsyHC
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 8, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 8, 2019, at $135.62
Tuesday Oct 8, 2019 |
$135.62 Close Price |
($4.06) (-2.91%) Change |
$134.42 - $138.65 Day's Range |
2.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Zw3kT73fLJmEIr7UZX0wD98lFykpFxkv
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 9, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 9, 2019, at $137.20
Wednesday Oct 9, 2019 |
$137.20 Close Price |
$1.58 (1.17%) Change |
$136.21 - $137.75 Day's Range |
1.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=rUvu8EFqcpkcIs8Zt1D2UtzT9-jZB8VM
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 10, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 10, 2019, at $138.76
Thursday Oct 10, 2019 |
$138.76 Close Price |
$1.56 (1.14%) Change |
$136.19 - $139.42 Day's Range |
1.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=juuuwbrrQ5lMIowuOpO8D6YWxF07NSXw
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 11, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 11, 2019, at $138.72
Friday Oct 11, 2019 |
$138.72 Close Price |
($0.04) (-0.03%) Change |
$138.69 - $141.99 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=GDvYxvUCVpnHIhMGtxDkkPDNB2FaE3RU
News Release Issued: Oct 9, 2019 (4:15pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-10-09-Danaher-Schedules-Third-Quarter-2019-Earnings-Conference-Call
WASHINGTON, Oct. 9, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it will webcast its quarterly earnings conference call for the third quarter 2019 on Thursday, October 24, 2019 beginning at 8:00 a.m. ET and lasting approximately 1 hour.
The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
You can access the conference call by dialing 866-503-8675 within the U.S. or +1 786-815-8792 outside the U.S. a few minutes before 8:00 a.m. ET and notifying the operator that you are dialing in for Danaher's earnings conference call (access code 6177645). A replay of the conference call will be available shortly after the conclusion of the call until October 31, 2019. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations."
Danaher's earnings press release, the webcast slides and other related presentation materials will be posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings" beginning at 6:00 a.m. ET on the date of the earnings call and will remain available following the call.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=VuVMkN6P0Zk-IodCttBR5BbI1b6NoIUD
Hi,
Any interest on below datasets? Please advise
Best Regards,
Janet
From: Janet Chua [mailto:janet.chua@internationalb2bprospects.com]
Sent: Thursday, September 5, 2019 6:35 AM
To: '@'
Subject: Campaign for Q3
Hi ,
Do you handle email list purchase/data append projects at your company?
Target Industry: _____________
Target Geography: ______________
Target Job Title: ________________
I'll arrange for a few samples, counts and pricing
Waiting to hear from you.
Regards,
Janet
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 14, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 14, 2019, at $138.80
Monday Oct 14, 2019 |
$138.80 Close Price |
$0.08 (0.06%) Change |
$138.42 - $140.00 Day's Range |
1.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Fed3AfaJ45mFIuupC8S690YhYE1PPuFc
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 15, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 15, 2019, at $137.59
Tuesday Oct 15, 2019 |
$137.59 Close Price |
($1.21) (-0.87%) Change |
$137.59 - $140.70 Day's Range |
2.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=fqPBNvw9WZnKIrENAeeXQtVREMYAFCd-
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 16, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 16, 2019, at $137.39
Wednesday Oct 16, 2019 |
$137.39 Close Price |
($0.20) (-0.15%) Change |
$136.91 - $138.48 Day's Range |
2.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=hYhD9GHh4plAIic9O_kHbO2vpW4wrFTu
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 17, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 17, 2019, at $137.77
Thursday Oct 17, 2019 |
$137.77 Close Price |
$0.38 (0.28%) Change |
$137.59 - $138.50 Day's Range |
1.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=2EbxRKtcM5mgIpvlJe-WwOsjJbw-5Srd
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 18, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 18, 2019, at $138.01
Friday Oct 18, 2019 |
$138.01 Close Price |
$0.24 (0.17%) Change |
$137.01 - $138.58 Day's Range |
1.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=jmutayBXhJnIIl6GgCM9KFuBqAaDyZiF
News Release Issued: Oct 21, 2019 (1:00am EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-10-21-Danaher-Reaches-Agreement-To-Sell-Certain-Businesses-To-Sartorius-AG-As-Part-Of-The-GE-Biopharma-Acquisition-Regulatory-Process
WASHINGTON, Oct. 21, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced that it has signed an agreement to sell its label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses to Sartorius AG for approximately $750 million. The combined revenue of the businesses, which are part of Danaher's Life Sciences segment, was approximately $140 million in 2018.
Danaher entered into the agreement to sell these businesses as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business, and the closing of the Sartorius AG agreement is conditioned upon Danaher's closing its acquisition of the GE Biopharma business. Danaher's acquisition of the GE Biopharma business, the proposed regulatory remedies (the package of businesses being sold), the approval of Sartorius as the buyer in such remedies, and Sartorius' acquisition described above all remain subject to approvals from various regulatory authorities.
Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "This represents a significant step in the regulatory process toward closing the GE Biopharma acquisition. While timing around meeting all closing conditions, including regulatory approvals, is still uncertain, we remain very encouraged by the progress to date and expect closing of the transaction in the first quarter of 2020."
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including statements regarding the proposed sale of the product lines identified above, the acquisition of GE Biopharma, the expected timetable for completing the acquisition of GE Biopharma, anticipated regulatory approvals relating to the acquisition of GE Biopharma and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, are "forward-looking" statements within the meaning of the U.S. federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, general economic conditions and conditions affecting the industries in which Danaher and GE Biopharma operate; the uncertainty of regulatory approvals and the timing or conditionality thereof; the parties' ability to satisfy the acquisition agreement conditions and consummate the transaction on the anticipated timetable or at all; Danaher's ability to successfully integrate GE Biopharma's operations and employees with Danaher's existing business; and GE Biopharma's performance and maintenance of important business relationships. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2018 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for the first quarter of 2019 and second quarter of 2019. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's ability to successfully integrate GE Biopharma's operations and employees with Danaher's existing business, the ability to realize anticipated financial, tax and operational synergies and benefits, GE Biopharma's performance and maintenance of important business relationships.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=yEefwmWPypk3Iq5tGDBBzvzZPWBtfYxD
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 21, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 21, 2019, at $138.23
Monday Oct 21, 2019 |
$138.23 Close Price |
$0.22 (0.16%) Change |
$137.52 - $138.90 Day's Range |
1.3M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=uRq7BeG6jJl6IuCfW7GssKyIRc1ubws6
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 22, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 22, 2019, at $137.08
Tuesday Oct 22, 2019 |
$137.08 Close Price |
($1.15) (-0.83%) Change |
$136.97 - $139.73 Day's Range |
1.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=mxm2wAPHUJn6Ih-o-Xn4sIOSGCe-3fIU
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 23, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 23, 2019, at $138.45
Wednesday Oct 23, 2019 |
$138.45 Close Price |
$1.37 (1.00%) Change |
$137.40 - $139.00 Day's Range |
2.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=2kUHgHtzEZlMIgW-dUc2fbTdPEARgCuk
News Release Issued: Oct 24, 2019 (6:00am EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-10-24-Danaher-Reports-Third-Quarter-2019-Results
WASHINGTON, Oct. 24, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2019. For the quarter ended September 27, 2019, net earnings attributable to Danaher common stockholders were $648.4 million, or $0.89 per diluted share which represents a 4.5% year-over-year decrease from the comparable 2018 period.
Non-GAAP adjusted diluted net earnings per share for the third quarter 2019 were $1.16 which represents a 5.5% increase over the comparable 2018 period. For the third quarter 2019, revenues increased 4.0% year-over-year to $5.0 billion, with non-GAAP core revenue growth of 5.0%. Excluding our Dental segment, now named Envista (NYSE: NVST), non-GAAP core revenue growth for the third quarter 2019 was 6.0%.
For the fourth quarter 2019, the Company anticipates that diluted net earnings per share will be in the range of $1.06 to $1.09 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.32 to $1.35.
For the full year 2019, the Company now anticipates that diluted net earnings per share will be in the range of $3.38 to $3.41 versus previous guidance of $3.38 to $3.43. The Company now expects 2019 non-GAAP adjusted diluted net earnings per share to be $4.74 to $4.77. Both GAAP and non-GAAP earnings per share figures include the dilution from the 19.4% non-controlling interest of Envista the Company no longer owns.
Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "We are pleased by our strong third quarter performance as we delivered another quarter of 5% core revenue growth and solid margin expansion. We believe our ongoing investments in innovation and commercial initiatives helped to continue building sustainable competitive advantages across a number of our businesses."
"During the quarter we also made meaningful progress on our two most recent portfolio moves. On September 18th, our Dental business, now called Envista, started trading as a public company. I want to thank Amir Aghdaei and all the Envista associates for their contributions. We wish them the very best as they embark on this exciting new endeavor," Joyce added. "We also achieved several important milestones related to the GE Biopharma acquisition. Earlier this week, we announced the planned sale of certain businesses to Sartorius in connection with the regulatory approval process. In addition, we raised approximately $6.8 billion in euro-denominated debt in September to be used to fund the acquisition."
Joyce concluded, "We remain encouraged by our performance and are excited about the opportunities ahead. We believe our differentiated portfolio and the power of the Danaher Business System position us well through the end of 2019 and beyond."
Danaher will discuss its results during its quarterly investor conference call today starting at 8:00 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by dialing 866-503-8675 within the U.S. or by dialing +1 786-815-8792 outside the U.S. a few minutes before the 8:00 a.m. ET start and telling the operator that you are dialing in for Danaher's investor conference call (access code 6177645). A replay of the conference call will be available shortly after the conclusion of the call and until October 31, 2019. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations." In addition, presentation materials relating to Danaher's results have been posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings."
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
NON-GAAP MEASURES
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial performance for the fourth quarter and full year 2019 and opportunities and positioning for 2019 and beyond, the anticipated acquisition of GE Biopharma, the regulatory approval process related thereto and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's ability to successfully integrate GE Biopharma's operations and employees with Danaher's existing business, the ability to realize anticipated financial, tax and operational synergies and benefits, GE Biopharma's performance and maintenance of important business relationships, Danaher's ability to complete the anticipated distribution of its Dental business and achieve the intended benefits thereof, deterioration of or instability in the economy, the markets served by us or GE Biopharma and the financial markets, developments and uncertainties in U.S. policy stemming from the U.S. administration, such as changes in U.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity (including the impact of the additional debt Danaher expects to incur to finance the GE Biopharma acquisition), our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's decision to leave the EU and uncertainty relating to the terms and timing of such separation), disruptions relating to man-made and natural disasters and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2018 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for each of the first, second and third quarters of 2019. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
DANAHER CORPORATION AND SUBSIDIARIES | |||||||||||||||
CONSOLIDATED CONDENSED STATEMENTS OF EARNINGS (unaudited) | |||||||||||||||
($ and shares in millions, except per share amounts) | |||||||||||||||
Three-Month Period Ended | Nine-Month Period Ended | ||||||||||||||
September 27, | September 28, | September 27, | September 28, | ||||||||||||
Sales | $ | 5,037.3 | $ | 4,853.1 | $ | 15,073.8 | $ | 14,529.5 | |||||||
Cost of sales | (2,228.9) | (2,162.6) | (6,670.0) | (6,378.3) | |||||||||||
Gross profit | 2,808.4 | 2,690.5 | 8,403.8 | 8,151.2 | |||||||||||
Operating costs: | |||||||||||||||
Selling, general and administrative expenses | (1,654.7) | (1,558.6) | (5,009.9) | (4,798.4) | |||||||||||
Research and development expenses | (318.9) | (301.2) | (951.5) | (911.6) | |||||||||||
Operating profit | 834.8 | 830.7 | 2,442.4 | 2,441.2 | |||||||||||
Nonoperating income (expense): | |||||||||||||||
Other income, net | 4.4 | 9.1 | 15.9 | 25.2 | |||||||||||
Interest expense | (26.3) | (41.3) | (70.2) | (123.6) | |||||||||||
Interest income | 30.1 | 2.8 | 72.0 | 6.7 | |||||||||||
Earnings before income taxes | 843.0 | 801.3 | 2,460.1 | 2,349.5 | |||||||||||
Income taxes | (169.1) | (137.6) | (721.1) | (445.4) | |||||||||||
Net earnings | 673.9 | 663.7 | 1,739.0 | 1,904.1 | |||||||||||
Less: net earnings attributable to noncontrolling interests | (5.9) | — | (5.9) | — | |||||||||||
Net earnings attributable to Danaher stockholders | 668.0 | 663.7 | 1,733.1 | 1,904.1 | |||||||||||
Mandatory convertible preferred stock dividends | (19.6) | — | (48.8) | — | |||||||||||
Net earnings attributable to common stockholders | $ | 648.4 | $ | 663.7 | $ | 1,684.3 | $ | 1,904.1 | |||||||
Net earnings per common share: | |||||||||||||||
Basic | $ | 0.90 | $ | 0.95 | $ | 2.36 | $ | 2.72 | |||||||
Diluted | $ | 0.89 | $ | 0.93 | $ | 2.32 | $ | 2.68 | |||||||
Average common stock and common equivalent shares | |||||||||||||||
Basic | 718.8 | 701.4 | 714.7 | 700.1 | |||||||||||
Diluted | 729.3 | 710.6 | 725.2 | 709.9 | |||||||||||
This information is presented for reference only. A complete copy of Danaher's Form 10-Q financial statements is available on the Company's website (www.danaher.com). |
DANAHER CORPORATION | |||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||||||||||||
Adjusted Diluted Net Earnings Per Share | |||||||||||||||
Three-Month Period Ended | Nine-Month Period Ended | ||||||||||||||
September 27, 2019 1 | September 28, 2018 | September 27, 2019 1 | September 28, 2018 | ||||||||||||
Diluted Net Earnings Per Share (GAAP) | $ | 0.89 | $ | 0.93 | $ | 2.32 | $ | 2.68 | |||||||
Pretax amortization of acquisition-related intangible assets A | 0.24 | 0.25 | 0.73 | 0.75 | |||||||||||
Pretax Envista separation costs and costs related to | 0.03 | — | 0.06 | — | |||||||||||
Pretax transaction costs deemed significant and | 0.04 | — | 0.09 | — | |||||||||||
First quarter 2019 costs and estimated liabilities related | — | — | 0.05 | — | |||||||||||
Pretax acquisition-related transaction costs deemed | — | — | — | 0.02 | |||||||||||
Pretax gain on resolution of acquisition-related matters | — | — | — | (0.01) | |||||||||||
Tax effect of all adjustments reflected above H | (0.05) | (0.05) | (0.17) | (0.16) | |||||||||||
Discrete tax adjustments and other tax-related | — | (0.03) | 0.31 | (0.04) | |||||||||||
Declared dividends on the MCPS assuming "if- | 0.01 | — | 0.03 | — | |||||||||||
Adjusted Diluted Net Earnings Per Share (Non-GAAP) | $ | 1.16 | $ | 1.10 | $ | 3.42 | $ | 3.24 |
1 | Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock ("MCPS") had been converted into shares of common stock. |
DANAHER CORPORATION | |||||||||||||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||||||||||||
(continued) | |||||||||||||||
Forecasted Adjusted Diluted Net Earnings Per Share 2 | |||||||||||||||
Three-Month Period Ending December 31, 2019 3 | Year Ending December 31, 2019 3 | ||||||||||||||
Low End | High End | Low End | High End | ||||||||||||
Forecasted Diluted Net Earnings Per Share (GAAP) | $ | 1.06 | $ | 1.09 | $ | 3.38 | $ | 3.41 | |||||||
Anticipated pretax amortization of acquisition-related | 0.23 | 0.23 | 0.96 | 0.96 | |||||||||||
Pretax Envista separation costs and costs related to | — | — | 0.06 | 0.06 | |||||||||||
Anticipated pretax transaction costs deemed significant | 0.06 | 0.06 | 0.15 | 0.15 | |||||||||||
First quarter 2019 costs and estimated liabilities related | — | — | 0.05 | 0.05 | |||||||||||
Early extinguishment of debt G | 0.01 | 0.01 | 0.01 | 0.01 | |||||||||||
Tax effect of all adjustments reflected above H | (0.05) | (0.05) | (0.22) | (0.22) | |||||||||||
Discrete tax adjustments and other tax-related | — | — | 0.31 | 0.31 | |||||||||||
Declared and anticipated dividends on the MCPS | 0.01 | 0.01 | 0.04 | 0.04 | |||||||||||
Forecasted Adjusted Diluted Net Earnings Per Share (Non-GAAP) | $ | 1.32 | $ | 1.35 | $ | 4.74 | $ | 4.77 |
2 | These forward-looking estimates do not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as certain future gains or losses on the sale of investments, acquisition or divestiture-related gains or charges (other than related to the GE Biopharma acquisition), discrete tax items and legal contingency provisions. |
3 | Each of the per share amounts above was calculated assuming MCPS had been converted into shares of common stock. |
Adjusted Diluted Share Outstanding | |||||||||||
Forecasted | |||||||||||
Three-Month | Nine-Month | Three-Month | Year Ending | ||||||||
September 27, | September 27, | December 31, | December 31, | ||||||||
(shares in millions) | |||||||||||
Average common stock and common equivalent shares | 729.3 | 725.2 | 730.6 | 726.5 | |||||||
Converted shares 4 | 11.6 | 9.3 | 12.0 | 10.0 | |||||||
Adjusted average common stock and common equivalent | 740.9 | 734.5 | 742.6 | 736.5 |
4 | The number of converted shares assumes the conversion of all 1.65 million shares of common stock underlying the MCPS applying the "if-converted" method of accounting and using an average 20 trading-day trailing volume weighted average price ("VWAP") of $142.26 as of September 27, 2019. |
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures |
DANAHER CORPORATION | |||||
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |||||
(continued) | |||||
Core Revenue Growth 5 | |||||
% Change Three- | % Change Nine- | ||||
Total sales growth (GAAP) | 4.0 | % | 3.5 | % | |
Less the impact of: | |||||
Acquisitions | (0.5) | % | (1.0) | % | |
Currency exchange rates | 1.5 | % | 3.0 | % | |
Core revenue growth (Non-GAAP) | 5.0 | % | 5.5 | % |
Adjusted Core Revenue Growth 5 | |||||||||||
% Change Three-Month Period Ended | % Change Nine-Month Period Ended | ||||||||||
Total Danaher | Dental / Envista | Total Danaher | Dental / Envista | ||||||||
Total sales growth (GAAP) | 4.0 | % | (3.0) | % | 3.5 | % | (2.5) | % | |||
Less the impact of: | |||||||||||
Acquisitions | (0.5) | % | — | % | (1.0) | % | — | % | |||
Currency exchange rates | 1.5 | % | 1.5 | % | 3.0 | % | 2.5 | % | |||
Core revenue growth (Non-GAAP) | 5.0 | % | (1.5) | % | 5.5 | % | — | % | |||
Less the impact of Envista on Danaher's core | 1.0 | % | 0.5 | % | |||||||
Adjusted core revenue growth (Non-GAAP) | 6.0 | % | 6.0 | % |
5 | We use the term "core revenue" to refer to GAAP revenue excluding (1) sales from acquired businesses recorded prior to the first anniversary |
See the accompanying Notes to Reconciliation of GAAP to Non-GAAP Financial Measures |
DANAHER CORPORATION | |
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES | |
(continued) | |
Notes to Reconciliation of GAAP to Non-GAAP Financial Measures | |
A | Amortization of acquisition-related intangible assets in the following historical and forecasted periods ($ in millions) (only the pretax amounts set forth below are reflected in the amortization line item above): |
Forecasted | |||||||||||||||||||||||
Three-Month Period Ended | Nine-Month Period Ended | Three-Month | Year Ending | ||||||||||||||||||||
September 27, 2019 | September 28, 2018 | September 27, 2019 | September 28, 2018 | December 31, 2019 | December 31, 2019 | ||||||||||||||||||
Pretax | $ | 177.9 | $ | 174.1 | $ | 536.6 | $ | 527.5 | $ | 173.7 | $ | 710.3 | |||||||||||
After-tax | 143.2 | 139.1 | 430.9 | 420.4 | 139.5 | 570.4 |
Pretax amortization for the three-month period and year ending December 31, 2019, has been reduced by $4.3 million pretax as reported in this line item, $3.5 million after-tax to reflect the amount that will be allocated to the Envista noncontrolling interest. | |
B | Pretax costs incurred in the three-month period ended September 27, 2019, ($25 million pretax as reported in this line item, $22 million after-tax), the nine-month period ended September 27, 2019, and year ending December 31, 2019, ($47 million pretax as reported in this line item, $41 million after-tax) related to preparation for the Envista separation and initial public offering primarily related to professional fees for legal, tax, finance and information technology services and duplicative general and administrative costs related to establishing a public company infrastructure for the business including incremental salaries, benefits and rent expense. |
C | Pretax costs incurred (or anticipated to be incurred, as applicable) for transaction costs deemed significant and integration preparation costs in the three-month period ended September 27, 2019, ($30 million pretax as reported in this line item, $28 million after-tax), the nine-month period ended September 27, 2019, ($63 million pretax as reported in this line item, $57 million after-tax), the three-month period ending December 31, 2019, ($49 million pretax as reported in this line item, $43 million after-tax) and the year ending December 31, 2019, ($112 million pretax as reported in this line item, $100 million after-tax) related to the anticipated GE Biopharma acquisition. The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company's larger acquisitions) if it determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period. |
D | Provision for potential costs and liabilities in connection with a legal contingency ($36 million pretax as presented in this line item, $29 million after-tax) recorded in the first quarter of 2019. |
E | Acquisition-related transaction costs deemed significant ($15 million pretax as presented in this line item, $13 million after-tax), and fair value adjustments to inventory ($1 million pretax as presented in this line item, $0.8 million after-tax), in each case related to the acquisition of IDT and incurred in the second quarter of 2018. |
F | Net gains on resolution of acquisition-related matters in the Life Sciences segment ($9 million pretax as presented in this line item, $7 million after-tax) for the second quarter of 2018. |
G | Loss on early extinguishment of debt resulting from "make-whole" payments associated with the retirement of the 2020 U.S. Notes and the 2020 Assumed Pall Notes ($7 million pretax as reported in this line item, $5 million after-tax) in the three-month period ending December 31, 2019. |
H | This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher's overall estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends. |
I | Discrete tax adjustments and other tax-related adjustments for the nine-month period ended September 27, 2019, includes the impact of net discrete tax charges of $227 million or $0.31 per diluted share. The discrete tax matters relate primarily to changes in estimates associated with prior period uncertain tax positions and audit settlements, net of the release of valuation allowances associated with certain foreign tax credits and tax benefits resulting from a change in law. The Company anticipates excess tax benefits from stock compensation of approximately $7 million per quarter and therefore excludes benefits in excess of this amount in the calculation of Adjusted Diluted Net Earnings Per Share. |
J | In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of our 4.75% MCPS. Dividends on the MCPS are payable on a cumulative basis at an annual rate of 4.75% on the liquidation preference of $1,000 per share. Unless earlier converted, each share of MCPS will automatically convert on April 15, 2022 into between 6.6382 and 8.1318 shares of Danaher's common stock, subject to further anti-dilution adjustments. The number of shares of Danaher's common stock issuable on conversion of the MCPS will be determined based on the VWAP per share of our common stock over the 20 consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately before April 15, 2022. For the purposes of calculating adjusted earnings per share, the Company has excluded the anticipated MCPS cash dividends and assumed the "if-converted" method of share dilution (the incremental shares of common stock deemed outstanding applying the "if-converted" method of calculating share dilution are referred to as the "Converted Shares.") The Company believes that using the "if-converted" method provides additional insight to investors on the anticipated impact of the MCPS once they are converted into common stock no later than April 15, 2022. |
Statement Regarding Non-GAAP Measures
Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering additional ways of viewing Danaher Corporation's ("Danaher" or the "Company") results that, when reconciled to the corresponding GAAP measure, help our investors to:
Management uses these non-GAAP measures to measure the Company's operating and financial performance, and uses core revenue and non-GAAP measures similar to Adjusted Diluted Net Earnings Per Share in the Company's executive compensation program.
The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Ne36JfKuaJnlIovUVRZpT46V44D6qsPY
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Oct 24, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ZmybmRtk05ngIhnTSczQWeq0yX8NhI2Q
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 24, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 24, 2019, at $136.44
Thursday Oct 24, 2019 |
$136.44 Close Price |
($2.01) (-1.45%) Change |
$135.69 - $138.33 Day's Range |
2.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=JvXY2BRu_JnyIgXkxitEKeaBGPGZJYq3
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 25, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 25, 2019, at $135.87
Friday Oct 25, 2019 |
$135.87 Close Price |
($0.57) (-0.42%) Change |
$135.08 - $136.31 Day's Range |
2.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=GmECR2yCg5mYIuZAfr1JBGBaSWE0GAdi
News Release Issued: Oct 28, 2019 (4:15pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-10-28-Danaher-To-Present-At-Baird-Global-Industrial-Conference
WASHINGTON, Oct. 28, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Thomas P. Joyce, Jr., will be presenting at the Baird Global Industrial Conference in Chicago on Tuesday, November 5, 2019 at 10:30 a.m. CT. The audio will be simultaneously webcast on and the presentation will be archived on www.danaher.com.
About Danaher
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=euCHTDA6L5lYIg79Roy-fCTM7hBqbwku
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 28, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 28, 2019, at $136.21
Monday Oct 28, 2019 |
$136.21 Close Price |
$0.34 (0.25%) Change |
$136.02 - $137.51 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=CPdaNaXCxJloIilt7I85LYM68zmOfLrG
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Oct 28, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=yK94xG2zi5mfIk5hYbKNbRLhBBBbem1Y
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Oct 28, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=JyHZp2V4NJkSItPc4eFaVg-ofte708TA
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Oct 28, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=H9V3k6ZydJmBImMa0lpPjd-nUtvfejVo
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Oct 28, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=yEJHRtYqnpl-IrXqU6DXiVWRkDD_rTf5
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Oct 28, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=EZTUjjHR5pkXIm72_2TkIOIFjlNMb9sf
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form FWP filed on Oct 30, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=btG8XDZ2FpnxInmkPTX0EtmYuvDm9qrS
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 29, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 29, 2019, at $137.27
Tuesday Oct 29, 2019 |
$137.27 Close Price |
$1.06 (0.78%) Change |
$135.78 - $138.71 Day's Range |
2.3M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=T4EszkVKV5nuIsr2cEQ6dkt5eVwqMEHO
News Release Issued: Oct 29, 2019 (11:01pm EDT)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-10-29-Danaher-Announces-Pricing-Of-Senior-Notes-Offering
WASHINGTON, Oct. 29, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher") announced today that its wholly owned subsidiary, DH Europe Finance II S.à r.l. ("Danaher International II"), has priced an offering of:
Danaher estimates that the net proceeds from the sale of the senior notes in this offering will be approximately $3.97 billion, after deducting the underwriting discounts and estimated offering expenses payable by Danaher. Danaher anticipates using the net proceeds to fund a portion of the cash consideration payable for, and certain costs associated with, its acquisition of the Biopharma Business of GE Life Sciences (the "GE Biopharma Acquisition"). Pending completion of the GE Biopharma Acquisition, Danaher may invest the net proceeds of the offering in short-term bank deposits or invest them in interest-bearing, investment-grade securities. The senior notes will be fully and unconditionally guaranteed on a senior unsecured basis by Danaher. The offering is expected to close on November 7, 2019, subject to customary closing conditions.
The offering is being made pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission.
The offering of senior notes may be made only by means of a prospectus and prospectus supplement. A copy of the prospectus and prospectus supplement relating to the securities can be obtained by calling BofA Securities, Inc., toll-free at 1-800-294-1322, Mizuho Securities USA LLC, toll-free at 1-866-271-7403, MUFG Securities Americas Inc., toll-free at 1-877-649-6848, U.S. Bancorp Investments, Inc., toll-free at 1-877-558-2607, or Wells Fargo Securities, LLC, toll-free at 1-800-645-3751.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, the senior notes or any other securities, nor shall there be any offer, solicitation or sale of any security mentioned in this press release in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Danaher
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
Forward-Looking Statements
Statements in this release that are not strictly historical, including the statements regarding the offering of the senior notes, the anticipated use of proceeds and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be "forward-looking statements" within the meaning of the federal securities laws. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in Danaher's SEC filings, including Danaher's 2018 Annual Report on Form 10-K and Danaher's Quarterly Reports on Form 10-Q for each of the first, second and third quarters of 2019. These forward-looking statements speak only as of the date of this release and Danaher and Danaher International II do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=JGkCsPTZDJnvItCd_ZmzqwpidiMLNzM1
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 424B5 filed on Oct 29, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=UB7ywVuG4pnUIkUeuDzZ300k_MKZtLuw
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 30, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 30, 2019, at $138.25
Wednesday Oct 30, 2019 |
$138.25 Close Price |
$0.98 (0.71%) Change |
$136.80 - $138.81 Day's Range |
3.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=w8Xgxmj9jZnXIqFlpm1SqjHhWzj8lWNx
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Oct 31, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=2yfwfsThx5nuInccnRsvDiHEnYZKlhuf
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 424B5 filed on Oct 31, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=PUFPJtJnM5lBIrx3TbCQVQKa01cX-1ow
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Oct 31, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Oct 31, 2019, at $137.82
Thursday Oct 31, 2019 |
$137.82 Close Price |
($0.43) (-0.31%) Change |
$136.66 - $138.70 Day's Range |
2.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=aCGK7AvcXpk9IkYMAEMicYiMZUznoOZF
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 1, 2019 (4:10pm EDT)
Danaher Corporation (NYSE:DHR) has closed today, Nov 1, 2019, at $136.57
Friday Nov 1, 2019 |
$136.57 Close Price |
($1.25) (-0.91%) Change |
$136.53 - $139.33 Day's Range |
2.3M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=AsvhzZYhaZl4IvQohLkp2v372NAEFnc3
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 4, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 4, 2019, at $135.22
Monday Nov 4, 2019 |
$135.22 Close Price |
($1.35) (-0.99%) Change |
$135.20 - $137.99 Day's Range |
2.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=77Ay7FNR95kaIr0-oocD9DBjcvby2MGG
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 5, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 5, 2019, at $133.47
Tuesday Nov 5, 2019 |
$133.47 Close Price |
($1.75) (-1.29%) Change |
$132.88 - $135.55 Day's Range |
3.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=k7XKjwmcQZkFImPP2DvFPTiwgy4Cd2X2
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 6, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 6, 2019, at $134.86
Wednesday Nov 6, 2019 |
$134.86 Close Price |
$1.39 (1.04%) Change |
$133.35 - $135.05 Day's Range |
2.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=KZ4t4Zwawpm5In4y4CEUopk2IvQvQ67y
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 7, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 7, 2019, at $134.50
Thursday Nov 7, 2019 |
$134.50 Close Price |
($0.36) (-0.27%) Change |
$134.07 - $135.22 Day's Range |
2.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=zhJ2TcGqEZlLIskWHE03W5uw7FSIOc0z
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Nov 7, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=mh42EATjbpnoIshmlpsOFjwx_T4uXXJF
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 8, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 8, 2019, at $135.23
Friday Nov 8, 2019 |
$135.23 Close Price |
$0.73 (0.54%) Change |
$134.37 - $135.62 Day's Range |
1.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=UDv8Mq2waJmVIt5u-IiVdn9YfnQbYrvj
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 11, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 11, 2019, at $134.52
Monday Nov 11, 2019 |
$134.52 Close Price |
($0.71) (-0.53%) Change |
$134.17 - $135.74 Day's Range |
1.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=dpkcZxenwZnsIt14aJaUU_TQz0vcqpWv
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 12, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 12, 2019, at $135.54
Tuesday Nov 12, 2019 |
$135.54 Close Price |
$1.02 (0.76%) Change |
$134.53 - $136.29 Day's Range |
1.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Ef66hwkCvJllIqxV0l4VhqgZJmJCaplA
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 3 filed on Nov 13, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=dufkPRvEPpn6IoowogjJHdVp1RpLK3OY
News Release Issued: Nov 13, 2019 (4:15pm EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-11-13-Danaher-Announces-Appointment-of-Jessica-L-Mega-MD-MPH-and-Pardis-C-Sabeti-MD-D-Phil-to-Danaher-Board
WASHINGTON, Nov. 13, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it has appointed Jessica L. Mega, MD, MPH and Pardis C. Sabeti, MD, D.Phil to its Board of Directors.
Dr. Mega is currently Chief Medical and Scientific Officer of Verily Life Sciences LLC, an Alphabet, Inc. company, where she has served since March 2015. Prior to joining Verily, she served as Cardiologist and Senior Investigator at Brigham & Women's. Dr. Mega has also served as a faculty member at Harvard Medical School and a senior investigator with the TIMI Study Group, where she helped lead international trials evaluating novel cardiovascular therapies and directed the genetics program.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine and Harvard School of Public Health. She completed her Internal Medicine Residency at Brigham and Women's Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology and has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards. Dr. Mega is also a Fellow of the American Heart Association (AHA) and the American College of Cardiology (ACC).
Dr. Sabeti is currently an Investigator for Howard Hughes Medical Institute, a non-profit medical research organization, where she has served since November 2015. Dr. Sabeti is a professor at both the Center for Systems Biology and the Department of Organismic and Evolutionary Biology at Harvard University and the Department of Immunology and Infectious Disease at Harvard School of Public Health. She is also a Broad Institute Member and a leader in the Broad's Infectious Disease and Microbiome Program.
Dr. Sabeti is a graduate of the Massachusetts Institute of Technology, University of Oxford (as a Rhodes Scholar) and Harvard Medical School. She is a World Economic Forum Young Global Leader and a National Geographic Emerging Explorer. In 2014, she was named a TIME magazine "Person of the Year" as one of the Ebola fighters and in 2015 as one of TIME's "100 Most Influential People." Her awards include the 2012 Smithsonian American Ingenuity Award for Natural Science, an Ellis Island Medal of Honor, and the 2017 Richard Lounsbery Award from the National Academy of Sciences.
Steven M. Rales, Chairman of the Board of Danaher Corporation, said "We are very pleased to welcome Drs. Mega and Sabeti to the Danaher Board of Directors. Their inspiring and diverse expertise in some of the most promising areas of science will provide valuable insights to Danaher as we continue to live our Shared Purpose, Helping Realize Life's Potential."
About Danaher
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=zz4nrhMggplpIurzJ6GMN4oheBhBKk7m
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 13, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 13, 2019, at $137.05
Wednesday Nov 13, 2019 |
$137.05 Close Price |
$1.51 (1.11%) Change |
$134.46 - $137.70 Day's Range |
4.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=KxfNVxguxJm0Ir18-Ba3Hc3RIvisegVV
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 3 filed on Nov 13, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=va3xJjwHKZnZIg4utDgMRqOSXlZjaxN8
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Nov 13, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=6UxUAjNMc5mPIhtnowvIlGgvANBnxsoJ
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 14, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 14, 2019, at $136.15
Thursday Nov 14, 2019 |
$136.15 Close Price |
($0.90) (-0.66%) Change |
$135.13 - $137.14 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=TJygnhnBb5lXInnHlFMPjSVP-njDfSYz
News Release Issued: Nov 15, 2019 (6:30am EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-11-15-Danaher-Will-Commence-Exchange-Offer-Related-To-Divestiture-Of-Its-Remaining-Interest-In-Envista-Through-A-Split-Off
WASHINGTON, Nov. 15, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that it will commence an exchange offer related to the split-off of its remaining interest in Envista Holdings Corporation (NYSE: NVST). Envista completed its initial public offering (IPO) in September 2019, with Danaher retaining an 80.6 percent ownership interest in Envista. In the exchange offer, Danaher stockholders have the option to exchange all, some or none of their shares of Danaher common stock for shares of Envista common stock owned by Danaher, subject to the terms of the offer. The exchange offer is anticipated to be tax-free for participating Danaher stockholders in the United States, except with respect to cash received in lieu of a fractional share.
Danaher also announced today that, in connection with the split-off, it has received a waiver of the 180-day lock-up with respect to the shares of Envista common stock held by it from J.P. Morgan Securities LLC, joint lead manager of the Envista IPO.
The exchange offer is designed to permit Danaher stockholders to exchange all or a portion of their shares of Danaher common stock for shares of Envista common stock at a discount of 7 percent, subject to an upper limit of 5.5784 shares of Envista common stock for each share of Danaher common stock tendered in the exchange offer. If the upper limit is not in effect, for each $100 of Danaher common stock accepted in the exchange offer, tendering stockholders would receive approximately $107.53 of Envista common stock. The per-share values of Danaher common stock and Envista common stock will be determined by reference to the simple arithmetic average of the daily volume-weighted average prices of Danaher common stock and Envista common stock on the New York Stock Exchange during the three consecutive trading days ending on and including the second trading day preceding the expiration date of the exchange offer, which would be December 9, 10 and 11, 2019, if the exchange offer is not extended or terminated.
The final exchange ratio showing the number of shares of Envista common stock that Danaher stockholders participating in the exchange offer will receive for each share of Danaher common stock accepted for exchange, including whether the upper limit is in effect, will be announced by press release no later than 5:30 p.m., New York City time, on the second trading day immediately preceding the expiration date of the exchange offer. The exchange offer will expire at 12:00 midnight, New York City time, at the end of the day on December 13, 2019, unless terminated or extended.
The final exchange ratio, when announced, and a daily indicative exchange ratio beginning on the third trading day of the exchange offer period, also will be available at http://investors.danaher.com/envista-exchange-offer.
The completion of the exchange offer is subject to certain conditions, including: at least 38.36 million shares of Envista common stock being distributed in exchange for shares of Danaher common stock validly tendered in the exchange offer; and the receipt of an opinion of counsel that the exchange offer will qualify for tax-free treatment to Danaher and its participating stockholders.
Danaher owns 127.87 million shares of Envista common stock, which represent approximately 80.6 percent of the outstanding common stock of Envista. The maximum number of shares of Danaher common stock that will be accepted in the exchange offer equals 127.87 million divided by the final exchange ratio. The exchange offer will be subject to proration if the exchange offer is oversubscribed, and the number of shares accepted in the exchange offer may be fewer than the number of shares tendered. If the exchange offer is consummated but not fully subscribed, then the remaining shares of Envista common stock owned by Danaher will be distributed on a pro rata basis to Danaher stockholders whose shares of Danaher common stock remain outstanding after the consummation of the exchange offer.
The exchange offer is voluntary for Danaher stockholders. No action is necessary for Danaher stockholders who choose not to participate, and their existing Danaher shares will not be impacted.
The terms and conditions of the exchange offer will be more fully described in a registration statement on Form S-4 and Form S-1 (Registration Statement), including a prospectus (Prospectus) forming a part thereof, to be filed by Envista with the U.S. Securities and Exchange Commission (SEC) today and a tender offer statement on Schedule TO (Schedule TO) to be filed by Danaher with the SEC today.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC will serve as dealer managers for the exchange offer.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
This communication contains certain statements about Danaher and Envista that are forward-looking statements. Forward-looking statements are based on current expectations and assumptions regarding Danaher's and Envista's respective businesses, the economy and other future conditions. In addition, the forward-looking statements contained in this communication may include statements about the expected effects on Danaher and Envista of the exchange offer, the anticipated timing and benefits of the exchange offer, Danaher's and Envista's anticipated financial results, and all other statements in this communication that are not historical facts.
Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and are detailed more fully in Danaher's and Envista's respective periodic reports filed from time to time with the SEC, the Registration Statement, including the Prospectus forming a part thereof, the Schedule TO and other exchange offer documents filed by Envista or Danaher, as applicable, with the SEC. Such uncertainties, risks and changes in circumstances could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and neither Danaher nor Envista undertakes any obligation to update publicly such statements to reflect subsequent events or circumstances, except to the extent required by applicable securities laws. Investors should not put undue reliance on forward-looking statements.
ADDITIONAL INFORMATION
This communication is for informational purposes only and is neither an offer to sell or the solicitation of an offer to buy any securities nor a recommendation as to whether investors should participate in the exchange offer. The offer will be made solely by the Prospectus. The Prospectus will contain important information about the exchange offer, Danaher, Envista, and related matters, and Danaher will deliver the Prospectus to holders of Danaher common stock. Investors and security holders are urged to read the Prospectus and any other relevant documents filed with the SEC, when they become available and before making any investment decision, because they contain important information about Danaher, Envista and the exchange offer. None of Danaher, Envista, or any of their respective directors or officers makes any recommendation as to whether investors should participate in the exchange offer.
Envista will file with the SEC the Registration Statement, including the Prospectus forming a part thereof, and Danaher will file with the SEC the Schedule TO, which will contain important information about the exchange offer. Holders of Danaher common stock may obtain copies of the Prospectus, the Registration Statement, the Schedule TO, other related documents, and any other information that Danaher and Envista file electronically with the SEC free of charge at the SEC's website at www.sec.gov.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=hm7fx4vwJplXIqPiO04vQ_5xPpOuK0Y3
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=tqMuDZXJ25nwIsQouqNoIgP4i2FNu7Nm
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form SC TO-I filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=bvkA7wRu9pmeIlWFgdyVRU1t5EXnTULw
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=U7cfwZGC6ZlzImW3-UfyZpX3uUGNj7gW
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 15, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 15, 2019, at $142.99
Friday Nov 15, 2019 |
$142.99 Close Price |
$6.84 (5.02%) Change |
$138.97 - $143.03 Day's Range |
13.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=rPc6v26KSZlCIskiADMcNAUv322U-dWt
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=je4bRnEzR5n0Isyd5ZI3IoRbFQFh595P
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=DnZ2T8G2OZkzImn3v0orSdymSupibPxV
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ugEVUqtFaJlNIoajAeQ9Rwlf6JY7O2IH
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=wsAMphJJppnDIgA-5oxudV7DvyKCwJhp
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 15, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=pUbC67jgP5mzIqN9Vxq_-lSffPP4hdJ-
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=8hCtcYZTBpm2Iiwv0Z2ImZbaj_Xtl24a
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=WAAxugvPOpmVIscT78xvCiJv-2CNUkDO
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=VAFXZKTvUJkMIui_575_VDXrqsYXqCnr
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 18, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 18, 2019, at $140.23
Monday Nov 18, 2019 |
$140.23 Close Price |
($2.76) (-1.93%) Change |
$140.11 - $143.08 Day's Range |
5.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=vqPZg2WkFJnNIryzSbegoZGGj0BVgV39
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=W3AZfEdaXJlkIlVZPIpNr32McuJRcwpa
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=TtwFYCrmv5lNIs1jBN7a6oOlECQZJkln
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=JgCdHenTvZkwIoHM1-JfqfE6_ph85lK7
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=WddVaDzkc5mmIqnGrn8Oo2Qb5-IP7H4v
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=GcWDaVbCSpkWIpzXLDY8qn7jXabjuVb9
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Nov 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=DYBGcbj2dpllIoWGc4oA9RONTaCxTCZ6
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 19, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 19, 2019, at $143.60
Tuesday Nov 19, 2019 |
$143.60 Close Price |
$3.37 (2.40%) Change |
$139.25 - $143.80 Day's Range |
7.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=GeHZBzxntJnvIjB6SqrRMjmbGRdGWvP9
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 19, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=VwdasThc9Zk4IrTjCrmij1nivRpNXewk
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 20, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=WevepxMJnZmnIuaTNWF4-mO12KkoyYHJ
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 20, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 20, 2019, at $142.96
Wednesday Nov 20, 2019 |
$142.96 Close Price |
($0.64) (-0.45%) Change |
$142.44 - $143.82 Day's Range |
6.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=DFzDypNPzJliIgm60EVoZTQnk7nWPoFi
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 22, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 22, 2019, at $143.32
Friday Nov 22, 2019 |
$143.32 Close Price |
$0.14 (0.10%) Change |
$142.46 - $143.85 Day's Range |
4.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=qUtE9kPKQ5mwIjNafNuf2QfcobedY5bO
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 21, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=HbkPhHWnVplvIhB49n-RIjEjeTPcsOO4
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 25, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 25, 2019, at $144.94
Monday Nov 25, 2019 |
$144.94 Close Price |
$1.62 (1.13%) Change |
$143.65 - $145.00 Day's Range |
5.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=79Br3Njvu5n_ItAU_RzgpAfEdh5pozLM
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 25, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=yhqhHXm9spkjIjsA2H1AiGqH1krgqY36
News Release Issued: Nov 27, 2019 (4:30pm EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-11-27-Danaher-To-Present-At-Evercore-ISI-HealthCONx-Conference
WASHINGTON, Nov. 27, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Evercore ISI HealthCONx Conference on Thursday, December 5, 2019 at 8:45 a.m. ET. The audio will be simultaneously webcast and then archived on www.danaher.com.
About Danaher
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=k8j4vkJKTplKIlS4AmZaW3sWUZoJSRXr
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 22, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=HsZG2pbNapl3Itew-Lov2BTD3a_cA_1W
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 27, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 27, 2019, at $146.59
Wednesday Nov 27, 2019 |
$146.59 Close Price |
$0.61 (0.42%) Change |
$145.77 - $147.20 Day's Range |
8.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=na3xztMAc5mTIgD-dNMq-vzs8zd5hhNy
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 27, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=asZaxfhTjJnWIr8_nQKkjx1kznG2ab40
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 26, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 26, 2019, at $145.98
Tuesday Nov 26, 2019 |
$145.98 Close Price |
$1.04 (0.72%) Change |
$144.74 - $146.40 Day's Range |
8.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=rCHDEXwn9pk3IgpkEC73FoglC1_-h9VD
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 29, 2019 (3:30pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 29, 2019, at $145.98
Friday Nov 29, 2019 |
$145.98 Close Price |
($0.61) (-0.42%) Change |
$145.21 - $147.00 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=v9GxvKWV5pmyIg3g_XD2VNSTatHBExzL
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 2, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 2, 2019, at $145.69
Monday Dec 2, 2019 |
$145.69 Close Price |
($0.29) (-0.20%) Change |
$144.07 - $146.68 Day's Range |
8.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=MWE6EwuN-ZlaIrTNSeBS0bl-tkLto-Nx
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Nov 21, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Nov 21, 2019, at $143.18
Thursday Nov 21, 2019 |
$143.18 Close Price |
$0.22 (0.15%) Change |
$141.05 - $143.28 Day's Range |
7.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=zXhZwuGE2Zm7IgFKjwN0iwn-lVB4ds--
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Nov 26, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ygtKqhc2H5myIp_OTzvl-ZVnScjx-DKt
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 3, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 3, 2019, at $146.69
Tuesday Dec 3, 2019 |
$146.69 Close Price |
$1.00 (0.69%) Change |
$144.11 - $146.99 Day's Range |
9.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=dAZdm4CpCpnOIs_KGMK3lFNd9bfl1Bfb
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 4, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 4, 2019, at $147.31
Wednesday Dec 4, 2019 |
$147.31 Close Price |
$0.62 (0.42%) Change |
$145.97 - $149.61 Day's Range |
13.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=47C6AvJKaplFImbE6IuEPwR31ek_zSpl
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 4, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=4s9rqATgqJmaIt3zrURWV22aq3gzs9-Y
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 5, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 5, 2019, at $147.19
Thursday Dec 5, 2019 |
$147.19 Close Price |
($0.12) (-0.08%) Change |
$145.51 - $147.30 Day's Range |
13.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=uGYY9zxndZnlIjLz4Rk-DTij3DHrhYKb
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 5, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=h2AsBBk3RJnUIqEVu6F47sVKznQ9okSR
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 6, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 6, 2019, at $148.22
Friday Dec 6, 2019 |
$148.22 Close Price |
$1.03 (0.70%) Change |
$146.79 - $148.94 Day's Range |
20.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=UvjyUCKDi5kjIn4wvpB2k0hnM0_Uu9K2
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 6, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=DPzgJJguiZlDIglOADskDWD6TBTLDNRj
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 9, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 9, 2019, at $147.53
Monday Dec 9, 2019 |
$147.53 Close Price |
($0.69) (-0.47%) Change |
$147.27 - $149.31 Day's Range |
31.1M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=y4DUKqKp5JlLIjgv5n74UkznuYUaPojF
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 9, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=tfbjutjcj5m1Io9fPsxv53jg9tcb77wA
News Release Issued: Dec 10, 2019 (4:10pm EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-12-10-Danaher-Announces-Quarterly-Dividend
WASHINGTON, Dec. 10, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.17 per share of its common stock, payable on January 31, 2020 to holders of record on December 27, 2019. In addition, Danaher announced today that its Board of Directors has approved a quarterly cash dividend of $11.875 per share of its 4.75% Series A Mandatory Convertible Preferred Stock, payable on January 15, 2020 to holders of record on December 31, 2019.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Pxc3Fqm6NZnbIqxf3XlD3KEl2riVuMy5
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 10, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 10, 2019, at $148.84
Tuesday Dec 10, 2019 |
$148.84 Close Price |
$1.31 (0.89%) Change |
$146.24 - $148.94 Day's Range |
39.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ffj3KYaY4plzIrj_uY_ttdkdjIqBNREw
News Release Issued: Dec 11, 2019 (4:42pm EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-12-11-Danaher-Announces-Final-Exchange-Ratio-Of-5-5784-for-Envista-Exchange-Offer
WASHINGTON, Dec. 11, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today the final exchange ratio for its previously announced offer to holders of shares of Danaher common stock to exchange their shares of Danaher common stock for shares of common stock of Envista Holdings Corporation (NYSE: NVST) owned by Danaher.
For each share of Danaher common stock that is validly tendered and not validly withdrawn by stockholders and that is accepted pursuant to the exchange offer, Danaher will deliver 5.5784 shares of Envista common stock to or at the direction of any such tendering stockholder.
The final calculated per-share value of Danaher common stock and the final calculated per-share value of Envista common stock, in each case determined in the manner described in the exchange offer prospectus, would have resulted in an exchange ratio of more than the upper limit of 5.5784. Accordingly, the final exchange ratio has been set at 5.5784 shares of Envista common stock for each share of Danaher common stock accepted in the exchange offer.
Because the exchange offer will be subject to proration if it is oversubscribed, the number of shares of Danaher common stock that Danaher accepts in the exchange offer may be less than the number of shares tendered. Based on the final exchange ratio, Danaher would accept for exchange approximately 22,921,984 shares of its common stock upon consummation of a fully subscribed exchange offer.
The exchange offer is currently scheduled to expire at 12:00 midnight, New York City time, at the end of the day on December 13, 2019, unless the exchange offer is extended or terminated.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the dealer managers for the exchange offer.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
This communication contains certain statements about Danaher and Envista that are forward-looking statements. Forward-looking statements are based on current expectations and assumptions regarding Danaher's and Envista's respective businesses, the economy and other future conditions. In addition, the forward-looking statements contained in this communication may include statements about the expected effects on Danaher and Envista of the exchange offer, the anticipated timing and benefits of the exchange offer, Danaher's and Envista's anticipated financial results, and all other statements in this communication that are not historical facts.
Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and are detailed more fully in Danaher's and Envista's respective periodic reports filed from time to time with the Securities and Exchange Commission (the "SEC"), the registration statement on Form S-4 and Form S-1 filed by Envista (the "Registration Statement"), including a prospectus (the "Prospectus") forming a part thereof, the tender offer statement on Schedule TO filed by Danaher (the "Schedule TO") and other exchange offer documents filed by Envista or Danaher, as applicable, with the SEC. Such uncertainties, risks and changes in circumstances could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and neither Danaher nor Envista undertakes any obligation to update publicly such statements to reflect subsequent events or circumstances, except to the extent required by applicable securities laws. Investors should not put undue reliance on forward-looking statements.
ADDITIONAL INFORMATION
This communication is for informational purposes only and is neither an offer to sell or the solicitation of an offer to buy any securities nor a recommendation as to whether investors should participate in the exchange offer. The offer will be made solely by the Prospectus. The Prospectus contains important information about the exchange offer, Danaher, Envista, and related matters, and Danaher will deliver the Prospectus to holders of Danaher common stock. Investors and security holders are urged to read the Prospectus and any other relevant documents filed with the SEC, when they become available and before making any investment decision, because they contain important information about Danaher, Envista and the exchange offer. None of Danaher, Envista, or any of their respective directors or officers or any of the dealer managers makes any recommendation as to whether investors should participate in the exchange offer.
Envista has filed with the SEC the Registration Statement, including the Prospectus forming a part thereof, and Danaher has filed with the SEC the Schedule TO, which contain important information about the exchange offer. Holders of Danaher common stock may obtain copies of the Prospectus, the Registration Statement, the Schedule TO, other related documents, and any other information that Danaher and Envista file electronically with the SEC free of charge at the SEC's website at www.sec.gov. Holders of Danaher common stock will also be able to obtain a copy of the Prospectus by clicking on the appropriate link on http://investors.danaher.com/envista-exchange-offer.
Danaher has retained Okapi Partners LLC as the information agent for the exchange offer. If you have any questions about the terms of the exchange offer or how to participate, you may contact the information agent at 877-566-1922 (toll-free for stockholders, banks and brokers) or +1-212-297-0720 (all others outside the U.S.).
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=D7tWDHC9_JmnImjfhlQTH2UC9pz72r1f
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 11, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 11, 2019, at $149.67
Wednesday Dec 11, 2019 |
$149.67 Close Price |
$0.83 (0.56%) Change |
$148.19 - $150.47 Day's Range |
53.3M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=KC3KaD4q4pmXIggFzzOhCd6VlDAi0qaI
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 11, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=RTXxAtZd5ZlkIiy4mtCytCM-ZE6ho0_G
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 11, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=8je6DWeHzJkaItC7J_Sqad3crOCBECxU
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form SC TO-I/A filed on Dec 11, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Hyezn8fJ1JnTIkWWUQvuhXduyaZt-eL2
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 12, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 12, 2019, at $151.30
Thursday Dec 12, 2019 |
$151.30 Close Price |
$1.63 (1.09%) Change |
$149.07 - $153.02 Day's Range |
73.7M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=cK6zPtK3npl9ImJ-LuVEj5rh05ttlpnv
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 12, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=MRvyma2w2JnwIvAp6SeIsFeGoKBz9tQ1
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 13, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=3TE3eBy6x5nSIu7SREqBvDdiQViZWwH5
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 13, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 13, 2019, at $148.52
Friday Dec 13, 2019 |
$148.52 Close Price |
($2.78) (-1.84%) Change |
$148.28 - $152.06 Day's Range |
64.4M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=aAMGXtNyJZm-IkE73VjbEYvqN0PUu3IU
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 16, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 16, 2019, at $151.44
Monday Dec 16, 2019 |
$151.44 Close Price |
$2.92 (1.97%) Change |
$148.03 - $153.54 Day's Range |
91.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=6Kp6DTpEVZkaIrl20Q35h0crTDEyj_K1
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form SC TO-I/A filed on Dec 16, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=fw2YEbAA6ZkHIuDtxYWKG9kYlocXqBXp
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 16, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=hdUjWGrsSpldInw864-LazsLGpAdkwYy
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Dec 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=deWtjtUABpmaIlxl5LI0NZWwX7a1iBOO
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form SC TO-I/A filed on Dec 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Ceyrg3r46JkjIhiADkh2SPHsru1LMak0
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Dec 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Eq9CjNWf45kpIvWz-KJerq3QpxS5pmHf
News Release Issued: Dec 16, 2019 (6:00am EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-12-16-Danaher-Announces-Preliminary-Results-Of-Envista-Exchange-Offer
WASHINGTON, Dec. 16, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today the preliminary results of its previously announced offer to holders of shares of Danaher common stock to exchange their shares of Danaher common stock for shares of common stock of Envista Holdings Corporation (NYSE: NVST) owned by Danaher. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on December 13, 2019. Under the terms of the exchange offer, 5.5784 shares of Envista common stock will be exchanged for each share of Danaher common stock accepted in the exchange offer.
According to the exchange agent, Computershare Trust Company, N.A., 305,594,776 shares of Danaher common stock were validly tendered and not validly withdrawn, including 123,273,497 shares that were tendered by notice of guaranteed delivery. Because the exchange offer was oversubscribed, Danaher will accept only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Stockholders who owned fewer than 100 shares of Danaher common stock, or an "odd-lot," who have validly tendered all of their shares, will not be subject to proration, in accordance with the terms of the exchange offer.
Danaher intends to accept 22,921,984 of the tendered shares in exchange for the 127,868,000 shares of Envista common stock owned by Danaher. Based on the preliminary results, it is estimated that approximately 7.22 percent of the tendered shares of Danaher common stock will be exchanged, assuming all shares tendered by guaranteed delivery procedures are delivered under the terms of the exchange offer. This estimated preliminary proration factor is subject to change based on the number of tendered shares that satisfy the guaranteed delivery procedures, as well as the number of "odd-lot" shares that were validly tendered and are not subject to proration. Danaher expects to announce the final proration factor promptly following December 17, 2019, the date of expiration of the guaranteed delivery period. Shares of Danaher common stock tendered but not accepted for exchange will be returned to the tendering stockholders in book-entry form promptly after the final proration factor is announced.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are the dealer managers for the exchange offer. Evercore served as an advisor to Danaher for the exchange offer.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of approximately 71,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
This communication contains certain statements about Danaher and Envista that are forward-looking statements. Forward-looking statements are based on current expectations and assumptions regarding Danaher's and Envista's respective businesses, the economy and other future conditions. In addition, the forward-looking statements contained in this communication may include statements about the expected effects on Danaher and Envista of the exchange offer, the anticipated timing and benefits of the exchange offer, Danaher's and Envista's anticipated financial results, and all other statements in this communication that are not historical facts.
Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and are detailed more fully in Danaher's and Envista's respective periodic reports filed from time to time with the Securities and Exchange Commission (the "SEC"), the registration statement on Form S-4 and Form S-1 filed by Envista (the "Registration Statement"), including a prospectus (the "Prospectus") forming a part thereof, the tender offer statement on Schedule TO filed by Danaher (the "Schedule TO") and other exchange offer documents filed by Envista or Danaher, as applicable, with the SEC. Such uncertainties, risks and changes in circumstances could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and neither Danaher nor Envista undertakes any obligation to update publicly such statements to reflect subsequent events or circumstances, except to the extent required by applicable securities laws. Investors should not put undue reliance on forward-looking statements.
ADDITIONAL INFORMATION
This communication is for informational purposes only and is neither an offer to sell or the solicitation of an offer to buy any securities nor a recommendation as to whether investors should participate in the exchange offer. Investors and security holders are urged to read the Prospectus and any other relevant documents filed with the SEC, when they become available and before making any investment decision, because they contain important information about Danaher, Envista and the exchange offer. None of Danaher, Envista, or any of their respective directors or officers or any of the dealer managers makes any recommendation as to whether investors should participate in the exchange offer.
Envista has filed with the SEC the Registration Statement, including the Prospectus forming a part thereof, and Danaher has filed with the SEC the Schedule TO, which contain important information about the exchange offer. Holders of Danaher common stock may obtain copies of the Prospectus, the Registration Statement, the Schedule TO, other related documents, and any other information that Danaher and Envista file electronically with the SEC free of charge at the SEC's website at www.sec.gov. Holders of Danaher common stock will also be able to obtain a copy of the Prospectus by clicking on the appropriate link on http://investors.danaher.com/envista-exchange-offer.
Danaher has retained Okapi Partners LLC as the information agent for the exchange offer. If you have any questions about the terms of the exchange offer or how to participate, you may contact the information agent at 877-566-1922 (toll-free for stockholders, banks and brokers) or +1-212-297-0720 (all others outside the U.S.).
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=cVFuCgfmvJnhIlXn69wNC835nj4K32S-
News Release Issued: Dec 18, 2019 (7:35am EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2019-12-18-Danaher-Announces-Final-Results-Of-Envista-Exchange-Offer
WASHINGTON, Dec. 18, 2019 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today the final results of its previously announced offer to holders of shares of Danaher common stock to exchange their shares of Danaher common stock for shares of common stock of Envista Holdings Corporation (NYSE: NVST) owned by Danaher. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on December 13, 2019.
Based on the final count by the exchange agent, Computershare Trust Company, N.A., the final results of the exchange offer are as follows:
Today, Danaher accepted 22,921,984 of the tendered shares in exchange for the 127,868,000 shares of Envista common stock owned by Danaher. Because the exchange offer was oversubscribed, Danaher accepted only a portion of the shares of its common stock that were validly tendered and not validly withdrawn, on a pro rata basis in proportion to the number of shares tendered. Stockholders who owned fewer than 100 shares of Danaher common stock, or an "odd-lot," who validly tendered all of their shares, were not subject to proration, in accordance with the terms of the exchange offer. All shares validly tendered by eligible "odd-lot" stockholders have been accepted. The final proration factor of 7.2433% had been applied to all other validly tendered shares of Danaher common stock to determine the number of such shares that were accepted.
Shares of Danaher common stock tendered but not accepted for exchange will be returned to the tendering stockholders in book-entry form promptly. In addition, the exchange agent will promptly credit shares of Envista common stock for distribution in the exchange offer in book-entry form to accounts maintained by the Envista transfer agent for tendering stockholders whose shares of Danaher common stock were accepted in the exchange offer. Checks in lieu of fractional shares of Envista common stock will be delivered after the exchange agent has aggregated all fractional shares and sold them in the open market.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC served as the dealer managers for the exchange offer. Evercore served as an advisor to Danaher for the exchange offer.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of more than 60,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.
FORWARD-LOOKING STATEMENTS
This communication contains certain statements about Danaher and Envista that are forward-looking statements. Forward-looking statements are based on current expectations and assumptions regarding Danaher's and Envista's respective businesses, the economy and other future conditions. In addition, the forward-looking statements contained in this communication may include statements about the expected effects on Danaher and Envista of the exchange offer, the anticipated timing and benefits of the exchange offer, Danaher's and Envista's anticipated financial results, and all other statements in this communication that are not historical facts.
Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and are detailed more fully in Danaher's and Envista's respective periodic reports filed from time to time with the Securities and Exchange Commission (the "SEC"), the registration statement on Form S-4 and Form S-1 filed by Envista (the "Registration Statement"), including a prospectus (the "Prospectus") forming a part thereof, the tender offer statement on Schedule TO filed by Danaher (the "Schedule TO") and other exchange offer documents filed by Envista or Danaher, as applicable, with the SEC. Such uncertainties, risks and changes in circumstances could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and neither Danaher nor Envista undertakes any obligation to update publicly such statements to reflect subsequent events or circumstances, except to the extent required by applicable securities laws. Investors should not put undue reliance on forward-looking statements.
ADDITIONAL INFORMATION
This communication is for informational purposes only and is neither an offer to sell or the solicitation of an offer to buy any securities nor a recommendation as to whether investors should participate in the exchange offer. Investors and security holders are urged to read the Prospectus and any other relevant documents filed with the SEC, when they become available and before making any investment decision, because they contain important information about Danaher, Envista and the exchange offer. None of Danaher, Envista, or any of their respective directors or officers or any of the dealer managers makes any recommendation as to whether investors should participate in the exchange offer.
Envista has filed with the SEC the Registration Statement, including the Prospectus forming a part thereof, and Danaher has filed with the SEC the Schedule TO, which contain important information about the exchange offer. Holders of Danaher common stock may obtain copies of the Prospectus, the Registration Statement, the Schedule TO, other related documents, and any other information that Danaher and Envista file electronically with the SEC free of charge at the SEC's website at www.sec.gov. Holders of Danaher common stock will also be able to obtain a copy of the Prospectus by clicking on the appropriate link on http://investors.danaher.com/envista-exchange-offer.
Danaher has retained Okapi Partners LLC as the information agent for the exchange offer. If you have any questions about the terms of the exchange offer, you may contact the information agent at 877-566-1922 (toll-free for stockholders, banks and brokers) or +1-212-297-0720 (all others outside the U.S.).
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ZFdUGkpg7pk7IuTWIHrywVAlQ6gG9bLQ
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 17, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 17, 2019, at $150.77
Tuesday Dec 17, 2019 |
$150.77 Close Price |
($0.67) (-0.44%) Change |
$150.07 - $152.28 Day's Range |
26.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=PFF3vMwH_ZlmImTFuCxMZ8VPxx_5pDTi
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 8-K filed on Dec 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=cJcRXjYB7Zn1IuNvi3bAAlFekpqrQWTA
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 425 filed on Dec 18, 2019
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=tGC8YqbWepmsIjOEkpHZph81aOAD0FDr
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 18, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 18, 2019, at $150.01
Wednesday Dec 18, 2019 |
$150.01 Close Price |
($0.76) (-0.50%) Change |
$149.57 - $151.44 Day's Range |
30.8M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=3yUbvA7zDplbIqOkqAh6LUap-VTqFgFi
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 19, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 19, 2019, at $150.44
Thursday Dec 19, 2019 |
$150.44 Close Price |
$0.43 (0.29%) Change |
$149.17 - $154.00 Day's Range |
34.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=A7ud8fNbHZmaIl83abplwUmkxvPc0wo7
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 31, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 31, 2019, at $153.48
Tuesday Dec 31, 2019 |
$153.48 Close Price |
$0.64 (0.42%) Change |
$152.25 - $153.58 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=3wy7aHHbPZlyIrlj2W_NDXTzQhVVeLKH
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 20, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 20, 2019, at $152.85
Friday Dec 20, 2019 |
$152.85 Close Price |
$2.41 (1.60%) Change |
$150.74 - $153.05 Day's Range |
18.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=3ygn9fNJVJmMIvzfRur0bygvTvY-sSdx
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jan 3, 2020 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Jan 3, 2020, at $154.15
Friday Jan 3, 2020 |
$154.15 Close Price |
($0.96) (-0.62%) Change |
$152.43 - $155.31 Day's Range |
2.2M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=eJgJ7eRsS5mwIsWRSJBdOLqeN8kZjEjy
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 23, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 23, 2019, at $153.24
Monday Dec 23, 2019 |
$153.24 Close Price |
$0.39 (0.26%) Change |
$152.45 - $153.85 Day's Range |
13.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=uxBxpsNtJpnoIt5rN0FoDYIQeq7yffs8
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jan 2, 2020 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Jan 2, 2020, at $155.11
Thursday Jan 2, 2020 |
$155.11 Close Price |
$1.63 (1.06%) Change |
$153.13 - $155.24 Day's Range |
2.3M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=NzkjDaH4JplIIkNvdpxzOEyXLGa9xFq1
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 27, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 27, 2019, at $152.88
Friday Dec 27, 2019 |
$152.88 Close Price |
$0.06 (0.04%) Change |
$152.40 - $153.38 Day's Range |
2.6M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=PrTd87HHApnFIhAuoZsKEQIjRkJ58sbh
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Dec 30, 2019 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Dec 30, 2019, at $152.84
Monday Dec 30, 2019 |
$152.84 Close Price |
($0.04) (-0.03%) Change |
$152.15 - $152.98 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=qvT2AuGM4JkpIiCFG0f2NsEVb4-o9ADm
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Feb 4, 2020
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=fXZF2pK935k-ItdZpGnWkOh04IDeWTGL
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jan 10, 2020 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Jan 10, 2020, at $158.12
Friday Jan 10, 2020 |
$158.12 Close Price |
$0.45 (0.29%) Change |
$157.37 - $158.58 Day's Range |
2.0M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=KT6NqzREuJmAIhmPmdIuFmTOFeZmaJyx
News Release Issued: Jan 13, 2020 (4:15pm EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2020-01-13-Danaher-CEO-To-Comment-On-Financial-Performance
WASHINGTON, Jan. 13, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") announced today that its President and Chief Executive Officer, Thomas P. Joyce, Jr., will comment tomorrow on the Company's fourth quarter 2019 performance in a presentation at the J.P. Morgan Healthcare Conference in San Francisco, California at 8:00 a.m. PT.
Mr. Joyce will communicate that fourth quarter 2019 core revenue growth is expected to be above the Company's previously announced guidance, driven by better performance in its Life Sciences and Diagnostics segments. Mr. Joyce will also comment that adjusted diluted net earnings per share is expected to be at or above the high-end of the Company's previously announced guidance.
As previously announced, Danaher will hold its quarterly earnings conference call for the fourth quarter and year-end 2019 on Thursday, January 30, 2020 at 8:00 a.m. ET.
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of more than 60,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
FORWARD LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial performance for the fourth quarter of 2019 and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, deterioration of or instability in the economy, the markets we serve and the financial markets, developments and uncertainties in U.S. policy stemming from the U.S. administration, such as changes in U.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's decision to leave the EU and uncertainty relating to the terms and timing of such separation), disruptions relating to man-made and natural disasters and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2018 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for each of the first, second and third quarters of 2019. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
SOURCE Danaher Corporation
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=dxnRyAf92JlnIkEtQeOD1gGeRGclDqd_
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Feb 4, 2020
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=4UPFEd7MR5k5IhYW4BWla4jg-XbFUTgx
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jan 27, 2020 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Jan 27, 2020, at $161.20
Monday Jan 27, 2020 |
$161.20 Close Price |
($1.05) (-0.65%) Change |
$159.61 - $161.87 Day's Range |
2.3M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=7e4cJvvtfZluIvqo-Rfbh8C0PHbLyBAd
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 5 filed on Feb 4, 2020
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=b3MsXYqBxJnJIgXxqWjcNc3jtm1hDrrJ
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Feb 4, 2020 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Feb 4, 2020, at $162.76
Tuesday Feb 4, 2020 |
$162.76 Close Price |
$1.76 (1.09%) Change |
$162.45 - $163.80 Day's Range |
2.5M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=Czp3NxMWH5kcIv7y5OGDb0aKigXVqONY
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 5 filed on Feb 4, 2020
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=A6Ref4Kcf5nfItJPMUwYQIYCvmJ2-deF
Daily Closing Price for Danaher Corporation (NYSE:DHR) - Jan 24, 2020 (4:10pm EST)
Danaher Corporation (NYSE:DHR) has closed today, Jan 24, 2020, at $162.25
Friday Jan 24, 2020 |
$162.25 Close Price |
($0.23) (-0.14%) Change |
$161.62 - $163.51 Day's Range |
1.9M Volume |
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=28pZhXEF85lmIlwBFXbzIpYQi8M38DLV
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form SC 13G/A filed on Feb 10, 2020
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=fRjZEDfU3JklIqoLZfk0XvgyEzW9bsFW
The following document for Danaher Corporation (NYSE:DHR) was filed with the U.S. Securities and Exchange Commission.
SEC Form 4 filed on Feb 4, 2020
View all SEC filings for Danaher Corporation (NYSE:DHR)
Get more information about Danaher Corporation (NYSE:DHR)
To unsubscribe or change your settings click here:
http://investors.danaher.com/index.php?s=subscribe&code=ANP6ZnHzw5mHIpKPIAADLCc-9_gU2go9
News Release Issued: Jan 30, 2020 (6:00am EST)
To view this release online and get more information about Danaher Corporation: IR Room visit: http://investors.danaher.com/2020-01-30-Danaher-Reports-Fourth-Quarter-and-Full-Year-2019-Results
WASHINGTON, Jan. 30, 2020 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2019. All results in this release reflect only continuing operations unless otherwise noted.
For the quarter ended December 31, 2019, net earnings were $792.9 million, or $1.07 per diluted share which represents a 11.5% year-over-year increase from the comparable 2018 period.
Non-GAAP adjusted diluted net earnings per share for the fourth quarter 2019 were $1.28 which represents a 12.5% increase over the comparable 2018 period. For the fourth quarter 2019, revenues increased 5.5% year-over-year to $4.9 billion, with non-GAAP core revenue growth of 6.0%.
For the full year 2019, net earnings were $2.4 billion, or $3.26 per diluted share which represents a 4.0% year-over-year decrease. Non-GAAP adjusted diluted net earnings per share for 2019 were $4.42 per share, which represents a 9.0% increase over the comparable 2018 amount. Revenues for the full year 2019 increased 5.0% to $17.9 billion, with non-GAAP core revenue growth of 6.0%.
For the first quarter 2020, the Company anticipates that diluted net earnings per share will be in the range of $0.78 to $0.81 and non-GAAP adjusted diluted net earnings per share will be in the range of $1.06 to $1.09.
For the full year 2020, the Company anticipates that diluted net earnings per share will be in the range of $3.96 to $4.06 and non-GAAP adjusted diluted net earnings per share will be $4.80 to $4.90, which assumes non-GAAP core revenue growth of approximately 5.0%. These first quarter and full year 2020 estimated results do not include the impact of earnings from the pending GE Biopharma acquisition, which is expected to close in the first quarter of 2020.
Thomas P. Joyce, Jr., President and Chief Executive Officer, stated, "Our fourth quarter results wrapped up a tremendous 2019 for Danaher. For the full year, we achieved 6.0% core revenue growth with solid margin expansion and cash flow. We continued to capture market share in many of our businesses through new product innovation and enhanced commercial execution. In addition, we completed the split-off of our Dental platform in December and announced the pending acquisition of GE's Biopharma business."
Joyce added, "Through a combination of organic and inorganic initiatives, we have transformed Danaher into a higher growth, higher margin and higher recurring revenue company with leading positions in attractive end-markets. Our portfolio today -combined with the power of the Danaher Business System - positions us well to continue to deliver long-term shareholder value."
Danaher will discuss its results during its quarterly investor conference call today starting at 7:30 a.m. ET. The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com, under the subheading "Events & Presentations." A replay of the webcast will be available in the same section of Danaher's website shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.
The conference call can be accessed by dialing 866-503-8675 within the U.S. or by dialing +1 786-815-8792 outside the U.S. a few minutes before the 7:30 a.m. ET start and telling the operator that you are dialing in for Danaher's earnings conference call (access code 5867674). A replay of the conference call will be available shortly after the conclusion of the call and until February 13, 2020. You can access the replay dial-in information on the "Investors" section of Danaher's website under the subheading "Events & Presentations." In addition, presentation materials relating to Danaher's results have been posted to the "Investors" section of Danaher's website under the subheading "Quarterly Earnings."
ABOUT DANAHER
Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of more than 60,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential. For more information, please visit www.danaher.com.
NON-GAAP MEASURES
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. Calculations of these measures, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures and other information relating to these non-GAAP measures are included in the supplemental reconciliation schedule attached.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding the Company's anticipated financial performance for the first quarter and full year 2020, the anticipated acquisition of the GE Biopharma business and the timing thereof, the Company's positioning in 2020 and beyond and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the uncertainty of regulatory approvals with respect to the GE Biopharma acquisition and the timing or conditionality thereof, the parties' ability to satisfy the acquisition agreement conditions and consummate the acquisition of GE Biopharma on the anticipated timetable and terms or at all, Danaher's ability to successfully integrate GE Biopharma's operations and employees with Danaher's existing business, the ability to realize anticipated financial, tax and operational synergies and benefits, GE Biopharma's performance and maintenance of important business relationships, deterioration of or instability in the economy, the markets we serve and the financial markets, developments and uncertainties in U.S. policy stemming from the U.S. administration, such as changes in U.S. trade and tariff policies and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, the impact of our debt obligations on our operations and liquidity, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole sources of supply, the impact of deregulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors (including the impact of the United Kingdom's decision to leave the EU and uncertainty relating to the terms of such separation), disruptions relating to man-made and natural disasters and pension plan costs. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2018 Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for each of the first, second and third quarters of 2019. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
DANAHER CORPORATION | |||||||||||||||
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations | |||||||||||||||
Three-Month Period Ended | Year Ended | ||||||||||||||
December 31, | December 31, | December 31, | December 31, | ||||||||||||
Diluted Net Earnings Per Common Share from Continuing Operations (GAAP) | $ | 1.07 | $ | 0.96 | $ | 3.26 | $ | 3.39 | |||||||
Pretax amortization of acquisition-related intangible assets A | 0.21 | 0.22 | 0.85 | 0.87 | |||||||||||
Pretax transaction costs deemed significant and integration | 0.04 | — | 0.13 | — | |||||||||||
Loss on early extinguishment of debt C | 0.01 | — | 0.01 | — | |||||||||||
Loss on partial settlement of a defined benefit plan D | 0.01 | — | 0.01 | — | |||||||||||
Pretax acquisition-related transaction costs deemed significant and | — | — | — | 0.02 | |||||||||||
Pretax gain on resolution of acquisition-related matters recognized | — | — | — | (0.01) | |||||||||||
Tax effect of all adjustments reflected above G | (0.05) | (0.04) | (0.17) | (0.17) | |||||||||||
Discrete tax adjustments and other tax-related adjustments H | (0.02) | — | 0.29 | (0.05) | |||||||||||
Declared dividends on the MCPS assuming "if-converted" method I | 0.01 | — | 0.04 |